

Synthesis of nucleoside analogues using acyclic diastereoselective reactions

Tommy Lussier,^{a,b} Marie-Ève Waltz,^a Garrett Freure,^a Philippe Mochirian,^a Starr Dostie,^a
Michel Prévost,^a and Yvan Guindon^{*a,b}

^a Bio-organic Chemistry Laboratory, Institut de Recherches Cliniques de Montréal (IRCM), Montréal,
Québec, H2W 1R7, Canada

^b Department of Chemistry, Université de Montréal, Montréal, Québec, H3C 3J7, Canada
Email: yvan.guindon@ircm.qc.ca

This paper is dedicated to Professor Stephen Hanessian, a mentor, colleague and friend


Received 12-03-2018

Accepted 03-11-2019

Published on line 04-29-2019

Abstract

The design of novel xylo-like nucleoside analogues bearing a C3' all-carbon quaternary center and a C2'-hydroxy substituent is described. Synthesis of this scaffold makes use of highly diastereoselective transformations on acyclic substrates. Central to the approach is formation of a 2,4-*syn* cyanohydrin from cyanide addition onto an aldehyde through a proposed seven-membered ring chelate using a bidentate Lewis acid. In addition, a highly diastereoselective Mukaiyama aldol reaction, an intramolecular radical atom cyclization, and thioaminal formation are used to generate this novel molecule. A series of related nucleoside analogues are being tested as antiviral and anticancer agents.



Keywords: Nucleoside analogues, xylo-like scaffolds, diastereoselective, acyclic, cyanohydrin, all-carbon quaternary stereo-center

Introduction

The implication of endogenous nucleosides and nucleotides in numerous biological pathways has, not surprisingly, inspired the development of various analogues as inhibitors of tumor growth and viral replication.^{1,2,3} Exploring the biological profiles of novel nucleoside analogues remains crucial, as shown by the recent approval of highly efficient antiviral drugs.⁴ We have initiated the syntheses of novel nucleoside analogues possessing an all-carbon quaternary stereogenic center at C3'.⁵⁻⁷ It is proposed that this chiral center could enhance target specificity in addition to providing opportunities for the incorporation of different pharmacophores. As illustrated in Figure 1, the hydroxymethyl substituent at C3' can have either a xylo/lyxo- (β -face) or ribo/arabino- (α -face) like orientation. The syntheses of C2'-fluoro analogues in which the hydroxymethyl substituent is located on the α -face (ribo-like scaffolds) has been previously reported by our group.⁸ Herein, we describe the synthesis of xylo-like analogues with a C2'-hydroxy group. Incorporation of a C3'-hydroxymethyl substituent with a β -orientation is a feature of apio-nucleosides, a class of analogues in which the hydroxymethyl normally found at C4' is shifted to C3'.⁹⁻¹¹ Presently, our scaffolds are being tested for their antiviral and anticancer properties; however, this novel xylo-like scaffold may also show potential in the design of new fungicides¹² and insecticides,¹³ as antimicrobial agents¹⁴ and acetylcholinesterase inhibitors¹⁵ all of which contain a xylo-furanoside core.





Figure 1. Nucleoside analogues bearing an all-carbon stereogenic center at C3'.

To construct our novel scaffold (**1**), a series of diastereoselective acyclic transformations were developed (Scheme 1). Using our two-step acyclic approach for the synthesis of nucleoside analogues, 1',2'-*trans* furanoside **2**, was formed from a kinetically controlled intramolecular cyclization of chiral thioaminal **3**. This 1,2-*syn* thioaminal resulted from diastereoselective nucleobase addition onto dithioacetal **4**.




Scheme 1. Retrosynthetic analysis of xylo-like analogues.

Central to our synthetic approach was a Lewis acid controlled diastereoselective cyanide (TMSCN) addition onto aldehyde **6** through a proposed seven-membered ring chelate to generate the C2'-hydroxy substituent from formation of the acyclic cyanohydrin **5**. An intramolecular silicon tethered free radical-based vinylation was used to construct the all-carbon stereogenic center in **7**, the substrate of which was accessed from a Mukaiyama aldol reaction between aldehyde **9** and enoxysilane **10**.


Results and Discussion

The reaction sequence to generate the targeted family of nucleoside analogues began with construction of the all-carbon quaternary center (Scheme 2). The key precursor **8a,b** for the intramolecular radical atom transfer cyclization was efficiently accessed by a three-step sequence involving a Mukaiyama aldol reaction^{16,17} between 2,3-isopropylidene-D-glyceraldehyde **9** and enoxysilanes **10** in the presence of $\text{MgBr}_2 \cdot \text{OEt}_2$.⁷ Treatment of the crude reaction mixture with HF-pyridine was necessary to remove undesired TMS protection of the oxygen at C3. The vinyl dimethylchlorosilane moiety was then installed on the resulting free alcohols to provide the 3,4-*anti* (**8a,b**) and 3,4-*syn* (**11a,b**) bromides in a 10:1 ratio and excellent yield (52%) over the three steps. Preference for the 3,4-*anti* stereochemistry has been proposed to occur through a Felkin-Ahn transition state.^{7,18-21} The steric hindrance imposed by the isopropylidene moiety of aldehyde **9** is likely to prohibit chelate formation between the aldehyde and α -oxygen.

Mukaiyama Aldol Reaction:




Atom Transfer Cyclization Reaction:



Scheme 2. Synthesis of the all-carbon quaternary center in **12**.


The free radical tandem cyclization/elimination reaction developed by our laboratory²² was then performed on **8a,b** in the presence of BET_3/O_2 (Scheme 2). The reaction was shown to proceed through a five-membered ring intermediate **A** (5-*exo*-trig) bearing a mixture of primary bromides.²² The stereochemistry of the newly formed quaternary center was proposed to originate from transition state **A** that minimizes intramolecular dipole-dipole interactions and allylic 1,3-strain.²³ The five-membered silyloxy ether intermediates (**A**) were cleaved upon treatment with $3\text{HF} \cdot \text{NEt}_3$ to give the 2,3-*syn* product **12** as the only observable diastereomer (>20:1) in 82% yield (see supporting information for stereochemical proofs).

Derivatization of **12** towards aldehyde **6** was achieved by first carrying out silylation of the secondary alcohol (Scheme 3). Reduction of the methyl ester and subsequent benzoylation generated the protected primary alcohol **13** in 68% yield over three steps. Cleavage of the acetonide and oxidation of the 1,2-diol using periodic acid led to an aldehyde that was immediately reduced to the corresponding primary alcohol **14** (85% yield over two steps), which was then protected with a benzyl group to give **15**. Deprotection of the primary benzoate with DIBAL-H followed by DMP oxidation provided aldehyde **6**.



Scheme 3. Synthesis of aldehyde **6** bearing an α -quaternary center and a β -hydroxy group.


The diastereoselective addition of cyanide^{24,25} onto aldehyde **6** was next studied. The desired xylo-like scaffold of the targeted nucleoside analogue (**1**) required a *syn* stereochemistry between the substituents at C2 and C4 of the resulting cyanohydrin (**5**). 1,2-Induction using a monodentate Lewis acid (**TS B** and **TS C**, Scheme 4) was expected to be poor, since two of the substituents of the quaternary center (methyl and vinyl) are sterically similar. The possibility of using the stereogenic secondary β -hydroxy group of the acyclic aldehyde was therefore considered.



Scheme 4. Transition states for diastereoselective cyanohydrin formation.

A bidentate Lewis acid could generate different reactive chelate intermediates. Chelation between the β -hydroxy group and the aldehyde is expected to give preference for the undesired 2,4-*anti* relationship through **TS D**, which avoids steric clash between the incoming nucleophile and the -CH₂OBn found in **TS E** (2,4-*syn* predictive transition state). However, the presence of the α -quaternary center could decrease the energy difference between **TS D** and **TS E**, the former having two gauche interactions between the substituents of the α - and β -stereogenic centers. Formation of a seven-membered ring intermediate (**TS F** and **TS G**) between the primary oxygen and the aldehyde could allow more flexibility for chelate formation and alleviate steric interactions between the incoming nucleophile and the quaternary center. Formation of the desired 2,4-*syn* cyanohydrin (**TS G**) in which nucleophilic attack occurs on the bottom face should be favored to avoid eclipsing interactions between the incoming nucleophile and the axial methyl of the quaternary center in **TS G** or with the β -hydroxy group in **TS F**.

To prevent potential competition between six- and seven-membered ring chelates, a bulky TBS group was incorporated onto the β -hydroxy of aldehyde **6**. Precomplexation of aldehyde **6** with an excess of MgBr₂·OEt₂²⁴ was followed by addition of the cyanide source (TMSCN) at -15 °C (Scheme 5). Cyanohydrin **5** was formed in an 8:1 ratio in favor of the 2,4 *syn* isomer in excellent yield (83% over two steps). It is noteworthy that the reaction of TMSCN and the aldehyde alone in DCM resulted in recuperation of the starting material, thus highlighting the need for a source of Lewis acid. Cyanide addition did occur in the presence of a Lewis base (NEt₃ or NH(*i*-Pr)₂) to furnish OTMS protected cyanohydrins (results not shown), albeit with low diastereoselectivity.²⁶ These observations are in accordance with precedent examples demonstrating that a Lewis acidic or basic species is needed to activate the TMSCN through formation of a pentacoordinate siliconate ion.^{27,28}



Scheme 5. Synthesis of 2,4-*syn* cyanohydrin.


To validate our initial hypotheses for 2,4-*syn* selectivity, a model study was undertaken at 0 °C (Table 1). As can be seen in entry 1, a 6:1 ratio in favor of the *syn* cyanohydrin was obtained at this temperature. When the reaction was performed with a monodentate Lewis acid, BF₃·OEt₂, an expected low diastereoselectivity of 1.5:1 was observed in favor of the 2,4-*syn* product (entry 2). Interestingly, when the TBS β -hydroxy protecting group was replaced by a benzyl or *p*-methoxybenzyl group, (aldehydes **17** and **19**), preference for the 2,4-*syn* cyanohydrin was maintained (entries 3 and 4) with MgBr₂·OEt₂, even though competing **TS D** could be at play. With aldehyde **21**, bearing a free β -hydroxy group (entry 5), a reversal of selectivity in favor of the 2,4-*anti* product was indeed noted suggesting reaction through **TS D**.

Suppressing the possibility of creating a seven-membered ring chelate by replacing the primary benzyl protecting group with a bulky silyl ether, as in aldehyde **23**, abolished the diastereoselection noted before (1.5:1, entry 6). Similarly, when the benzyl ether was replaced by its carbon equivalent as in **25**, a decrease in selectivity was observed (2.5:1, entry 7). To ensure that this loss of selectivity was not the result of having an α -gem-dimethyl instead of the stereogenic center, we prepared **27** and observed a high *syn* preference (11:1 entry 8 versus 6:1 entry 1) which suggests a greater interaction between the incoming nucleophile and olefin

in **TS G**. Taken together, these results support the intermediacy of a 7-membered ring chelate (**TS G**)²⁹⁻³¹ in inducing 2,4-*syn* diastereoselectivity for cyanohydrin formation in the presence of MgBr₂·OEt₂.

Interestingly, with the use of a titanium Lewis acid (Table 1, entries 9-13), formation of the 2,4-*anti* cyanohydrin could be favored. When aldehyde **19** bearing a β-PMB was reacted with 1.1 equivalents of TiCl₃(O*i*Pr), a 1:1 ratio of *syn* and *anti* cyanohydrins were formed (entry 9) in which the β-PMB was cleaved. Upon increasing the equivalents of TiCl₃(O*i*Pr) to 2.5 (entries 10 and 11) a 1:6 ratio was obtained in favor of the 2,4-*anti* diol **22b**. Not surprisingly, with a β-OTBS, preference for the 2,4-*syn* cyanohydrin **5a** was maintained (3:1 ratio, entry 12), favoring cyanation through 7-membered chelate **TS G** or monodentate activation.

Table 1. Diastereoselective cyanohydrin formation.



Entry	Aldehyde ^a	L.A.	Equiv. L.A.	R ⁵	R ⁴	R ³	Ratio (a:b) ^b	Cyanohydrin	Yield (%)
1	6	MgBr ₂ ·OEt ₂	5.0	OBn	OTBS	vinyl	6:1	5a,b	79
2	6	BF ₃ ·OEt ₂	1.5	OBn	OTBS	vinyl	1.5:1	5a,b	63
3	17	MgBr ₂ ·OEt ₂	5.0	OBn	OBn	vinyl	8:1 ^c	18a,b	81
4	19	MgBr ₂ ·OEt ₂	5.0	OBn	OPMB	vinyl	8:1	20a,b	93
5	21	MgBr ₂ ·OEt ₂	5.0	OBn	OH	vinyl	1:4	22a,b	89
6	23	MgBr ₂ ·OEt ₂	5.0	OTBDPS	OTBS	vinyl	1.5:1	24a,b	93
7	25	MgBr ₂ ·OEt ₂	5.0	CH ₂ CH ₂ Ph	OTBS	methyl	2.5:1	26a,b	82
8	27	MgBr ₂ ·OEt ₂	5.0	OBn	OTBS	methyl	11:1	28a,b	79
9	19	TiCl ₃ (O <i>i</i> Pr)	1.1	OBn	OPMB	vinyl	1:1	22a,b ^d	ND
10	19	TiCl ₃ (O <i>i</i> Pr)	2.5	OBn	OPMB	vinyl	1:6	22a,b ^d	59
11	21	TiCl ₃ (O <i>i</i> Pr)	2.5	OBn	OH	vinyl	1:6	22a,b	49
12	6	TiCl ₃ (O <i>i</i> Pr)	2.5	OBn	OTBS	vinyl	3:1	5a,b	68
13	17	TiCl ₃ (O <i>i</i> Pr)	2.5	OBn	OBn	vinyl	1:1 ^c	18a,b	91

^a Synthesis of racemic aldehydes **6**, **17**, **19**, **21**, **23**, **25** and **27** is described in the experimental section along with proofs of structure in the supporting information. The two cyanohydrin diastereomers were separated, deprotected to the corresponding diols and then protected as an acetonide. The relative stereochemistry of the *syn* and *anti*-acetonides was determined from 1D NOESY and the ¹³C chemical shifts of the acetal carbon and the gem-dimethyl substituents.^b 2,4-*Syn*:2,4-*anti* ratios determined by ¹H NMR analysis of the crude reaction mixture.

^c Relative stereochemistry not determined in this case. ^d PMB-cleaved, resulting in diol product.

NMR Studies. To help elucidate the preference for 2,4-*anti* cyanohydrin formation with aldehydes **19** (β-OPMB) and **21** (β-OH) in the presence of 2.5 equivalents of TiCl₃(O*i*Pr) (entries 10 and 11), low temperature ¹³C

NMR spectra of the complexed aldehydes were acquired in CD₂Cl₂ (Figure 2). The first observation made was that both aldehydes resulted in similar ¹³C spectra upon addition of 1.1 equivalents of TiCl₃(O*i*Pr), which indicates that the β-PMB of aldehyde **19** is cleaved before addition of the nucleophile.³² Complex spectra (not shown) were obtained with three new peaks in the carbonyl region. It is likely that these correspond to different intermediates that react unselectively to give mixtures of diastereomers (Table 1, entry 9). However, in the presence of 2.5 equivalents of TiCl₃(O*i*Pr) (Figure 2, upper spectrum) there is clearly only one complexed carbonyl species with a significant downfield (11.5 ppm) signal. In addition, the carbons corresponding to C3, C4 and C5 are also all shifted downfield, which supports their involvement in complex formation.





Figure 2. ¹³C NMR spectra of aldehyde **21** with 0.0 and 2.5 equiv. of TiCl₃(O*i*Pr) at 0 °C in CD₂Cl₂.

Although an X-ray structure of this titanium complex has yet to be determined, the above preliminary ¹³C NMR spectra support formation of a complex as in intermediate **E** (Scheme 6). Formation of this intermediate is supported by Gau's studies of titanium complexes,³³ where he noted the prevalence of hexacoordinated species. In addition, these studies suggested that the binding ability of various chemical entities to titanium was ⁻O*i*Pr > Cl⁻ > THF > Et₂O > PhCHO > μ-Cl⁻ > RCO₂M. Based on the ¹³C NMR data, the first step in the complexation of TiCl₃(O*i*Pr) with aldehydes **19** and **21** is formation of a covalent bond between the oxygen at C3 and the titanium resulting in intermediate **B** (Scheme 6). Following Gau's study, the second oxygen to coordinate would be the oxygen at C4 resulting in intermediate **C** in which the carbonyl is uncoordinated.




Scheme 6. Transition state for 2,4-*anti* cyanohydrin formation with 2.5 equivalents of $\text{TiCl}_3(\text{OiPr})$.

Although carbonyl activation is not necessary for cyanation to occur, ^{13}C NMR studies indicate that it is indeed complexed with the titanium. Upon addition of a second equivalent of $\text{TiCl}_3(\text{OiPr})$, intermediate **D** could be formed, but monodentate activation is not likely to provide high diastereoselectivities, as observed with 1.1 equivalents of $\text{TiCl}_3(\text{OiPr})$ (Table 1, entry 9). Formation of intermediate **E** in which both titaniums are coordinated to the oxygen at C3 would be consistent with the need for 2.5 equivalents of $\text{TiCl}_3(\text{OiPr})$ to reach higher levels of diastereoselectivity. Various titanium complexes were examined by density functional theory (DFT) calculations in Gaussian 09 (D.01) with tight SCF convergence³⁴ using the M062X³⁵/6-31G* level of theory in DCM with the polarizable continuum model (PCM).³⁶ Intermediate **E** in which the isopropoxide ligands are located *trans* to the C1-aldehyde and C4-OBn group was of lowest energy. Through NBO analysis, a weak interaction was observed between the chloride ligand and the C4'-Ti thus both titanium centers exist as hexacoordinate species. Although, it is also possible to form a bicyclic [3.2.1]-type complex with 2.5 equivalents of $\text{TiCl}_3(\text{OiPr})$, as previously proposed,³⁷ our preliminary ^{13}C NMR data is consistent with formation of intermediate **E** through initial displacement of a chloride ligand. Preferential attack of the cyanide opposite the β -alkyl chain in **TS H** would result in formation of the 2,4-*anti* cyanohydrin **22b**. Interestingly, when aldehyde **17** bearing a β -OBn group was reacted in the presence of 2.5 equivalents of $\text{TiCl}_3(\text{OiPr})$ (entry 13, Table 1), a 1:1 ratio of *syn* and *anti* cyanohydrins **18a,b** was obtained. The presence of this benzyl protecting group results in a reaction pathway not involving intermediate **E**.


Investigation of this cyanation reaction has demonstrated that the choice of Lewis acid and β -protecting group are key to reach high levels of diastereoselectivity in favor of the 2,4-*syn* or 2,4-*anti* cyanohydrin allowing access to either the xylo-like (this manuscript) or the lyxo-like nucleoside analogues. In addition, this cyanation reaction highlights the potential for other stereoselective nucleophilic additions onto aldehydes possessing an α -stereogenic center for which there are few literature examples.^{38,39}

To generate the novel nucleoside scaffold, the C2-protected 2,4-*syn* cyanohydrin **16** was first reduced with DIBAL-H and then transformed into di(ethylthio)acetal **4** in 70% yield (Scheme 7).



Scheme 7. Acyclic approach for the synthesis of nucleoside analogues.

At this point in the strategy, we made use of our novel two-step acyclic approach for the synthesis of nucleoside analogues,⁴⁰ the mechanism of which has been examined in detail using DFT calculations.^{8,41} We have recently reported the use of this strategy with a C3-quaternary center and a fluoride at C2,⁸ however, this is the first report of using this strategy with a thioaminal bearing a C2-hydroxy and a C3-quaternary center. An essential aspect of this strategy is the diastereoselective synthesis of a 1,2-*syn* thioaminal (**29**) from a dithioacetal (**4**). Activation of this acyclic dithioacetal with iodine and addition of silylated nucleobase (thymine or uracil) provided the 1,2-*syn* thioaminals in excellent diastereoselectivity (only one isomer could be detected by ¹H NMR) and yield. Formation of the 1,2-*syn* thioaminal proceeds through a S_N2-like mechanism in which the initially formed halothioether adopts a conformational preference orienting the C2-OTBS and the thioether moiety in close proximity to one another to maximize R–C2 and H–C2 sigma donation to the electron poor thiocarbenium intermediate in **TS I**. The presence of the counteranion (I⁻) stabilizes this transition state and prefers to be located on the opposite side of the incoming nucleobase.^{8,41} Selective removal of the less hindered C4-TBS protecting group provided the necessary thioaminals **30** and **31** in excellent yields. The next key step of our acyclic approach involves a stereospecific displacement of the activated sulfur of the thioaminal by the C4-hydroxy with inversion of configuration (O4'-C1 cyclization). This provided the D-1',2'-*trans* furanosides **32** (thymine, 71% yield) and **33** (uracil, 80% yield). Proof of structure for the nucleoside analogues was determined by 2D NOESY experiments (see supporting information). Transformation of the monosubstituted alkene of **32** and **33** into the desired primary alcohol was accomplished in five steps (Scheme 8). This monosubstituted alkene could serve as the starting point for a variety of chemical modifications to add heteroatoms and diverse functionalities. In this study, it was transformed into an hydroxymethyl group.



Scheme 8. Synthesis of xylo-like nucleoside analogues.

Dihydroxylation using osmium tetroxide followed by oxidative cleavage of the diol resulted in the corresponding aldehyde that was reduced using lithium borohydride providing the C3'-hydroxymethyl substituent. Removal of the C2'-TBS provided scaffolds **34** and **35** in 59% yield for these four steps. The desired xylo-like nucleoside analogues (**36** and **37**) were formed after removal of the primary benzyl protecting groups.

Conclusions

The synthesis of a novel class of xylo-like nucleoside analogues bearing a stereogenic quaternary center at C3' has been described. This acyclic synthetic route relies on highly diastereoselective chemical transformations investigated in our laboratory: an *anti* selective Mukaiyama aldol reaction, a *syn* selective intramolecular radical transfer cyclization, formation of a *syn* selective cyanohydrin followed by the synthesis and cyclization of a *syn* thioaminal. A key element of this route is the cyanide addition onto aldehydes activated through formation of proposed 7-membered ring chelates. These analogues and other molecules of this family are being tested for their antiviral and antiproliferative properties. The results of these tests will be reported in due course.

Experimental Section

General Comments. All reactions requiring anhydrous conditions were carried out under an atmosphere of nitrogen or argon in flame-dried glassware using standard syringe techniques. All anhydrous solvents were dried with 4 Å molecular sieves prior to use. The 4 Å molecular sieves (1–2 mm beads) were activated by heating at 180 °C for 48 hours under vacuum prior to adding to new bottles of solvent purged with argon. Commercially available reagents were used as received. Flash chromatography was performed on silica gel 60 (0.040 – 0.063 mm) using forced flow (flash chromatography) of the indicated solvent system or an automated flash purification system *Biotage Isolera One* (version 1.3.6). Analytical thin-layer chromatography (TLC) was carried out on pre-coated (0.25 mm) silica gel aluminum plates. Visualization was performed with U.V. short wavelength and/or revealed with ammonium molybdate or potassium permanganate solutions. ¹H NMR spectra were recorded at room temperature on a 500 MHz Varian Unity INOVA NMR spectrometer. The data are reported as follows: chemical shift in ppm referenced to residual solvent (CDCl₃ δ 7.26 ppm), multiplicity (s = singlet, d = doublet, dd = doublet of doublets, ddd = doublet of doublets of doublets, t = triplet, td = triplet of

doublets, m = multiplet, app = apparent), coupling constants (Hz), and integration. ^{13}C NMR spectra were recorded at room temperature using 100.6 (Varian VXR 400 NMR) or 126 MHz. The data are reported as follows: chemical shift in ppm referenced to residual solvent (CDCl_3 δ 77.16 ppm). Infrared spectra were recorded on a FTIR ABB Bomen (MB series) or a Bruker Platinum ATR (Alpha II series) spectrophotometer from a thin film of purified product and signals are reported in cm^{-1} . Mass spectra were recorded through electrospray ionization (ESI) positive ion mode using a Thermo Fischer LTQ Orbitrap XL. A Q exactive mass analyzer was used for HRMS measurements and were done by the *Plateforme de découvertes en protéomique* at l'Institut de Recherches Cliniques de Montréal (IRCM). Optical rotations were measured at room temperature from the sodium D line (589 nm) using a PerkinElmer 343 polarimeter and CDCl_3 as solvent unless otherwise noted and calculated using the formula: $[\alpha]_D = (100)\alpha_{\text{obs}}/(\ell \cdot c)$, where c = (g of substrate/100 ml of solvent) and ℓ = 1 dm. The characterization of chemical structures from X-ray data has been done at the Université de Montréal X-ray diffraction laboratory. Proofs of structure can be found in the supporting information.

General Procedure A: Reduction of ester

To a solution of ester in dry CH_2Cl_2 (67 mL, 0.20 M) at -40°C , DIBAL-H (3.0 equiv.) was added. The solution was stirred until the ester (1.0 equiv.) was all consumed (1h30 at -40°C) as determined by TLC. MeOH was added at -40°C until gas formation ceased. An aqueous solution of potassium sodium tartrate was added, and the reaction mixture was warmed to room temperature. The aqueous layer was extracted with Et_2O (3x). The organic layers were combined, dried over MgSO_4 , filtered and concentrated *in vacuo*.

General Procedure B: Oxidation of alcohol

To a solution of oxalyl chloride (1.3 equiv.) in anhydrous CH_2Cl_2 (0.10 M) at -78°C , dimethyl sulfoxide (2.3 equiv.) was added dropwise. The solution was stirred for 20 minutes at which point the alcohol (1.0 equiv.), as a 0.40 M solution in anhydrous CH_2Cl_2 , was added followed by stirring at -78°C for 1h. Triethylamine (5.0 equiv.) was added and the reaction mixture was warmed to room temperature over 45 minutes. An aqueous solution of NH_4Cl was added and the aqueous layer was extracted with Et_2O (3x). The organic layers were combined, dried over MgSO_4 , filtered and concentrated *in vacuo*.

General Procedure C: Cyanohydrin formation

To a solution of aldehyde (1.0 equiv.) in anhydrous CH_2Cl_2 (0.10 M) at 0°C , the appropriate Lewis acid, $\text{MgBr}_2 \cdot \text{OEt}_2$ (5.0 equiv.), $\text{BF}_3 \cdot \text{OEt}_2$ (1.5 equiv.), or $\text{TiCl}_3(\text{O}i\text{Pr})$ (1.1 or 2.5 equiv.), was added. The reaction mixture was stirred 5 minutes for precomplexation. TMSCN (2.0 equiv.) was then added. The solution was stirred until the aldehyde was all consumed, 1h at 0°C , as determined by TLC. An aqueous solution of NaHCO_3 was added and the aqueous layer was extracted with Et_2O (3x). The organic layers were combined, dried over MgSO_4 , filtered and concentrated *in vacuo*.

$\text{TiCl}_3(\text{O}i\text{Pr})$ was prepared by mixing one equivalent of $\text{Ti}(\text{O}i\text{Pr})_4$ with three equivalents of TiCl_4 in DCM.⁴²

Preparation of silylated nucleobases

To a suspension of the nucleobase in HMDS (2.7 equiv.) under inert atmosphere, $(\text{NH}_4)_2\text{SO}_4$ (0.10 equiv.) was added. The reaction mixture was refluxed until a clear solution was obtained (typically three hours). Upon cooling to room temperature, the solution was placed under high vacuum for approximately 1 hour to remove excess HMDS. A solution of the silylated nucleobase was made in dichloroethane.

Compounds 8a,b and 12 from Scheme 2:

(-)-Methyl (2*R*,3*R*)-2-bromo-3-[[dimethyl(vinyl)silyl]oxy]-3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-methylpropanoate (8a) and (+)-methyl (2*S*,3*R*)-2-bromo-3-[[dimethyl(vinyl)silyl]oxy]-3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-methylpropanoate (8b): To a 0°C solution of crude methyl (3*R*)-2-bromo-3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-hydroxy-2-methylpropanoate⁷ (4.8 g, 16 mmol, 1.0 equiv.) in CH_2Cl_2 (40 mL, 0.40 M),

imidazole (3.3 g, 48 mmol, 3.0 equiv.) was added in one portion. Upon complete dissolution of imidazole, chloro(dimethyl)vinylsilane (3.14 mL, 20.8 mmol, 1.30 equiv.) was added dropwise. The reaction was then warmed to room temperature and stirring continued for 16 hours at which point ^1H NMR showed complete conversion of starting material. The reaction mixture was quenched with water. The aqueous layer was extracted with CH_2Cl_2 (3 \times 25 mL), the organic layers were combined, washed with brine, dried over MgSO_4 , filtered and concentrated *in vacuo* to afford the crude product as a dark yellow oil. Coevaporation with toluene (2x) and purification using a silica pad (Hexanes/ Et_2O , 30:70) provided **8a,b** (3.2 g, 52% yield over 3 steps, 3,4-*anti* : 3,4-*syn* 10:1) as a light-yellow oil. The minor product from the aldol reaction (**11a,b**) could not be separated. **8a**: $R_f = 0.37$ (Hexanes/ Et_2O 90:10); $[\alpha]_{\text{D}}^{25} -2.7$ ($c = 2.0$, CH_2Cl_2); Molecular formula: $\text{C}_{14}\text{H}_{25}\text{BrO}_5\text{Si}$; MW: 381.34; IR (neat) ν_{max} 2985, 2953, 1744, 1250, 1053 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 6.15 (dd, J 20.3, 14.9 Hz, 1H), 6.02 (dd, J 14.9, 3.9 Hz, 1H), 5.75 (dd, J 20.3, 3.8 Hz, 1H), 4.62 – 4.57 (m, 2H), 3.98 – 3.91 (m, 2H), 3.78 (s, 3H), 1.77 (s, 3H), 1.46 (s, 3H), 1.35 (s, 3H), 0.24 (s, 3H), 0.23 (s, 3H) ppm; ^{13}C NMR (126 MHz, CDCl_3) δ 170.6, 137.7, 133.4, 108.1, 76.9, 75.9, 64.6, 61.4, 53.4, 26.2, 24.5, 23.8, -0.9, -1.3 ppm; HRMS calcd for $\text{C}_{14}\text{H}_{25}\text{BrO}_5\text{SiNa}$ [$\text{M}+\text{Na}^+$]: 403.0547; found 403.0533 (-3.5 ppm). **8b** (6:1 mix with 3,4-*syn* product): $R_f = 0.21$ (Hexanes/ Et_2O 90:10); $[\alpha]_{\text{D}}^{25} +11$ ($c = 0.8$, CH_2Cl_2); IR (neat) ν_{max} 2987, 2952, 1744, 1254, 1104 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 6.25 (dd, J 20.4, 14.9 Hz, 1H), 6.07 (dd, J 14.9, 3.7 Hz, 1H), 5.82 (dd, J 20.4, 3.7 Hz, 1H), 4.33 (d, J 7.2 Hz, 1H), 4.09 (dd, J 8.1, 6.5 Hz, 1H), 4.02 (dd, J 13.5, 6.5 Hz, 1H), 3.81 – 3.79 (m, 1H), 3.76 (s, 3H), 1.89 (s, 3H), 1.35 (s, 3H), 1.29 (s, 3H), 0.34 (s, 3H), 0.31 (s, 3H) ppm; ^{13}C NMR (126 MHz, CDCl_3) δ 170.8, 137.7, 133.7, 109.8, 78.4, 76.4, 68.3, 64.9, 52.9, 26.1, 25.1, 22.2, -0.7, -1.0 ppm; HRMS calcd for $\text{C}_{14}\text{H}_{25}\text{BrO}_5\text{SiNa}$ [$\text{M}+\text{Na}^+$]: 403.0547; found 403.0533 (-3.5 ppm).

(-)-Methyl (S)-2-((R)-[2,2-dimethyl-1,3-dioxolan-4-yl](hydroxy)methyl)-2-methylbut-3-enoate (12): To a solution of the α -bromo ester **8a,b** (2.0 g, 5.2 mmol, 1.0 equiv.) in toluene (11 mL, 0.50 M) at 0 $^\circ\text{C}$, BEt_3 (5.2 mL, 1.0 M, 1.0 equiv.) was added with a syringe pump over 4 hours. After completion of the reaction, ethanolamine (0.90 mL, 16 mmol, 3.0 equiv.) was added. The mixture was stirred for 30 minutes before it was transferred to a plastic vial and treated with $3\text{HF}\cdot\text{NEt}_3$ (1.3 mL, 7.9 mmol, 1.5 equiv.) at 0 $^\circ\text{C}$. The mixture was stirred at room temperature overnight. The crude solution was transferred dropwise into a cold solution of saturated NaHCO_3 . The aqueous layer was extracted with Et_2O (2x), the organic layers were combined, dried over MgSO_4 , filtered and concentrated *in vacuo*. The crude product (2,3-*syn*, dr >20:1) was purified by flash chromatography on silica gel (Hexanes/ Et_2O , 60:40) to give **12** (1.05 g, 82%) as a colorless oil. The minor 3,4-*syn* product from the Mukaiyama aldol (not characterized) could be separated. **12**: $R_f = 0.3$ (Hexanes/ EtOAc , 65:35); $[\alpha]_{\text{D}}^{25} -20$ ($c = 1.1$, CH_2Cl_2); Molecular formula: $\text{C}_{12}\text{H}_{20}\text{O}_5$; MW: 244.29; IR (neat) ν_{max} 1722 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 6.12 (dd, J 17.6, 10.8 Hz, 1H), 5.32 (d, J 10.8 Hz, 1H), 5.25 (d, J 17.6 Hz, 1H), 4.08 – 3.99 (m, 3H), 3.96 – 3.91 (m, 1H), 3.70 (s, 3H), 1.37 (s, 3H), 1.35 (s, 3H), 1.32 (s, 3H) ppm, OH signal missing possibly due to exchange in CDCl_3 ; ^{13}C NMR (126 MHz, CDCl_3) δ 175.0, 138.4, 117.3, 109.1, 76.1, 75.6, 67.2, 52.8, 52.4, 26.4, 25.4, 15.2 ppm; HRMS calcd for: $\text{C}_{12}\text{H}_{20}\text{O}_5\text{Na}$ [$\text{M}+\text{Na}^+$]: 267.1203; found 267.1204 (+0.4 ppm).

Compounds 13, 14, 15 and 6 from Scheme 3:

(+)-(R)-2-((S)-((tert-Butyldimethylsilyl)oxy)-[(R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-methylbut-3-en-1-yl benzoate (13): To a solution of secondary alcohol **12** (4.9 g, 20 mmol, 1.0 equiv.) in CH_2Cl_2 (25 mL, 0.80 M) at 0 $^\circ\text{C}$ pyridine (3.2 mL, 40 mmol, 2.0 equiv.) and TBSOTf (5.5 mL, 24 mmol, 1.2 equiv.) were added. The resulting mixture was stirred at room temperature for 16 hours before addition of Et_2O /Hexanes (1:1, 25 mL) and saturated aqueous NH_4Cl (30 mL). After stirring vigorously for 10 minutes, the layers were separated, and the aqueous layer extracted with Et_2O /Hexanes (1:1, 2 \times 30 mL). The organic fractions were combined and washed successively with 1N HCl (2 \times 40 mL), water and brine, dried over MgSO_4 , filtered and concentrated *in vacuo*. The crude residue (7.2 g, 99% yield) was coevaporated with toluene (2 \times 10 mL) and used directly in the

next reaction. A solution of the crude ester (7.2 g, 20 mmol, 1.0 equiv.) in CH₂Cl₂ (40 mL, 0.50 M) was cooled to -40 °C (MeCN/dry ice bath) followed by addition of DIBAL-H (45 mL, 45 mmol, 2.2 equiv.) over 10 minutes. After stirring 90 minutes at -40 °C, a saturated solution of aqueous Rochelle salt (60 mL) was slowly added followed by saturated aqueous Na₂CO₃ (10 mL) and Et₂O (40 mL). The biphasic mixture was warmed to room temperature and vigorously stirred until both phases were clear (about 2 hours). The aqueous layer was extracted with Et₂O (2 × 40 mL) and the combined organic fractions were washed with saturated aqueous Na₂CO₃ followed by brine, dried over MgSO₄, filtered and concentrated *in vacuo* to afford the crude primary alcohol as a colorless oil which was used directly in the next step. The crude primary alcohol (6.6 g, 20 mmol, 1.0 equiv.) was dissolved in CH₂Cl₂ (20 mL, 1.0 M) and pyridine (6.5 mL, 80 mmol, 4.0 equiv.) and DMAP (0.49 g, 4.0 mmol, 0.20 equiv.) were added. The resulting reaction mixture was cooled to 0 °C and benzoyl chloride (2.8 mL, 24 mmol, 1.2 equiv.) was added dropwise. The reaction mixture was slowly warmed to room temperature and stirred for 5 hours before being cooled to 0 °C followed by addition of ethylenediamine (0.94 mL, 14 mmol, 0.70 equiv.). After stirring 45 minutes, CH₂Cl₂ was evaporated and the residue diluted with Et₂O, loaded on a silica pad and eluted with Hexanes/EtOAc (1:1) to afford the crude product as an oil. Purification by flash column chromatography provided **13** as a colorless oil (5.9 g, 68% yield over 3 steps). *R*_f = 0.68 (Hexanes/EtOAc, 80:20); [α]_D²⁵ +24 (*c* = 2.6, CH₂Cl₂); Molecular formula: C₂₄H₃₈O₅Si; MW: 434.25; IR (neat) ν _{max} 1722 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.08 – 8.02 (m, 2H), 7.61 – 7.55 (m, 1H), 7.50 – 7.43 (m, 2H), 5.99 (dd, *J* 17.7, 11.0 Hz, 1H), 5.26 – 5.18 (m, 2H), 4.27 – 4.20 (m, 4H), 3.81 (d, *J* 7.5 Hz, 2H), 1.45 (s, 3H), 1.32 (s, 3H), 1.22 (s, 3H), 0.93 (s, 9H), 0.16 (s, 3H), 0.07 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 166.5, 139.0, 133.1, 130.4, 129.6, 128.6, 116.4, 110.1, 107.4, 76.2, 75.3, 69.4, 64.4, 45.1, 26.3, 24.9, 18.9, 18.6, -3.0, -4.4 ppm; HRMS calcd for: C₂₄H₃₈O₅SiNa [M+Na⁺]: 457.2381; found 457.2374 (-1.5 ppm).

(+)-(R)-2-[(S)-1-[(tert-Butyldimethylsilyl)oxy]-2-hydroxyethyl]-2-methylbut-3-en-1-yl benzoate (14): To a 0 °C solution of acetal **13** (5.2 g, 12 mmol, 1.0 equiv.) in EtOAc (120 mL, 0.10 M), periodic acid (4.1 g, 18 mmol, 1.5 equiv.) was added in one portion. The resulting heterogeneous mixture was stirred vigorously for 15 minutes at 0 °C and then at room temperature until complete conversion (typically 3-4 hours by TLC monitoring). The mixture was diluted with Et₂O (100 mL) and slowly poured into cold saturated aqueous Na₂S₂O₃ (75 mL) and saturated aqueous Na₂CO₃ (10 mL). After vigorously stirring 30 minutes, the aqueous layer was extracted with Et₂O (1 × 50 mL) and the combined organic fractions were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to afford the aldehyde (4.4 g, 100% yield, crude) which was used directly in the next step. ¹H NMR (500 MHz, CDCl₃) δ 9.59 (d, *J* 3.1 Hz, 1H), 8.04 – 7.99 (m, 2H), 7.63 – 7.56 (m, 1H), 7.52 – 7.43 (m, 2H), 6.10 (dd, *J* 17.7, 11.0 Hz, 1H), 5.29 (d, *J* 11.0 Hz, 1H), 5.24 (dd, *J* 17.6, 0.7 Hz, 1H), 4.35 (d, *J* 10.8 Hz, 1H), 4.23 (d, *J* 10.8 Hz, 1H), 3.94 (d, *J* 3.1 Hz, 1H), 1.24 (s, 3H), 0.94 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H) ppm. The crude aldehyde (4.4 g, 12 mmol, 1.0 equiv.) was dissolved in THF (60 mL, 0.20 M) and the resulting solution was cooled to -40 °C. LiBH₄ (2.0 M in THF, 6.0 mL, 12 mmol, 1.0 equiv.) was then added dropwise and the reaction mixture stirred at -40 °C for 1 hour. The reaction was quenched by slow addition of 0.1 N HCl (60 mL) and the biphasic mixture stirred vigorously for 30 minutes at room temperature at which point Et₂O was added. The aqueous layer was extracted with Et₂O (2 × 30 mL) and the combined organic layers washed with 1 N HCl (25 mL), water and brine, dried over MgSO₄, filtered and concentrated *in vacuo* to afford the crude primary alcohol. Purification by flash chromatography provided **14** as a colorless oil (3.7 g, 85% yield over 2 steps): *R*_f = 0.37 (Hexanes/EtOAc, 80:20); [α]_D²⁵ +4.8 (*c* = 6.3, CH₂Cl₂); Molecular formula: C₂₀H₃₂O₄Si; MW: 364.56; IR (neat) ν _{max} 3501, 1720, 1704 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.08 – 8.03 (m, 2H), 7.62 – 7.55 (m, 1H), 7.50 – 7.43 (m, 2H), 6.07 (dd, *J* 17.7, 11.0 Hz, 1H), 5.27 – 5.16 (m, 2H), 4.30 (d, *J* 10.8 Hz, 1H), 4.27 (d, *J* 10.8 Hz, 1H), 3.85 (dd, *J* 5.3, 3.5 Hz, 1H), 3.75 (ddd, *J* 11.5, 5.7, 3.6 Hz, 1H), 3.71 – 3.64 (m, 1H), 1.21 (s, 3H), 0.94 (s, 9H), 0.15 (s, 3H), 0.10 (s, 3H) ppm, OH signal missing possibly due to exchange in CDCl₃; ¹³C NMR (126 MHz, CDCl₃) δ 166.5,

139.8, 133.1, 130.4, 129.6, 128.6, 115.7, 76.9, 69.0, 64.3, 44.9, 26.1, 19.0, 18.4, -3.8, -4.7 ppm; HRMS calcd for $C_{20}H_{33}O_4Si$ [$M+H^+$]: 365.2143; found: 365.2165 (-6.0 ppm).

(+)-(R)-2-((S)-2-(Benzyloxy)-1-[(tert-butyldimethylsilyl)oxy]ethyl)-2-methylbut-3-en-1-yl benzoate (15): To a solution of primary alcohol **14** (3.7 g, 10 mmol, 1.0 equiv.) in cyclohexane/ CH_2Cl_2 (2:1, 100 mL, 0.10 M) at 0 °C, benzyl 2,2,2-trichloroacetimidate (2.4 mL, 13 mmol, 1.3 equiv.) and trifluoromethanesulfonic acid (0.13 mL, 1.5 mL, 0.15 equiv.) were added. The resulting suspension was stirred for 16 hours at room temperature at which point NEt_3 (0.7 mL, 5 mmol, 0.5 equiv.) was added and the volatiles removed *in vacuo*. Hexane was added, and the solids filtered over Celite. Purification by flash chromatography (Hexanes/ Et_2O) provided **15** as a colorless oil (3.8 g, 84%): $R_f = 0.51$ (Hexanes/ $EtOAc$, 90:10); $[\alpha]_D^{25} +9.8$ ($c = 3.6$, CH_2Cl_2); Molecular formula: $C_{27}H_{38}O_4Si$; MW: 454.68; IR (neat) ν_{max} 2953, 2928, 2855, 1720, 1269, 1108 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 8.10 – 8.03 (m, 2H), 7.61 – 7.56 (m, 1H), 7.51 – 7.43 (m, 2H), 7.42 – 7.27 (m, 5H), 6.05 (dd, J 17.7, 11.0 Hz, 1H), 5.24 – 5.17 (m, 2H), 4.54 (d, J 11.9 Hz, 1H), 4.48 (d, J 11.9 Hz, 1H), 4.34 (d, J 10.6 Hz, 1H), 4.27 (d, J 10.6 Hz, 1H), 3.99 (dd, J 6.4, 2.9 Hz, 1H), 3.67 (dd, J 10.0, 3.0 Hz, 1H), 3.39 (dd, J 10.0, 6.4 Hz, 1H), 1.22 (s, 3H), 0.92 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H) ppm; ^{13}C NMR (126 MHz, $CDCl_3$) δ 166.6, 139.5, 138.3, 133.0, 130.6, 129.6, 128.5, 128.4, 127.8, 127.7, 115.7, 75.9, 73.6, 73.4, 69.2, 45.0, 26.1, 18.8, 18.5, -3.8, -5.0 ppm; HRMS calcd for $C_{27}H_{39}O_4Si$ [$M+H^+$]: 455.2612; found 455.2592 (-4.4 ppm).

(+)-(R)-2-((S)-2-(Benzyloxy)-1-[(tert-butyldimethylsilyl)oxy]ethyl)-2-methylbut-3-en-1-ol (S1): To a -40 °C solution of benzoate **15** (3.2 g, 7.0 mmol, 1.0 equiv.) in CH_2Cl_2 (21 mL, 0.33M), DIBAL-H (1.0 M in hexanes, 17 mL, 17 mmol, 2.4 equiv.) was added over 10 minutes. The solution was stirred for 1 hour at -40 °C before addition of Et_2O (20 mL) followed by saturated aqueous Rochelle salt (30 mL). The biphasic mixture was warmed to room temperature and stirred vigorously for 2 hours. The aqueous layer was extracted with Et_2O (2 × 25 mL) and the combined organic fractions were washed with 0.1 N HCl, water and brine, dried over $MgSO_4$, filtered and concentrated *in vacuo*. Purification by flash chromatography provided primary alcohol **S1** as a colorless oil (1.5 g, 61% yield): $R_f = 0.41$ (Hexanes/ $EtOAc$, 80:20); $[\alpha]_D^{25} +2.9$ ($c = 3.0$, CH_2Cl_2); Molecular formula: $C_{20}H_{34}O_3Si$; MW: 350.57; IR (neat) ν_{max} 3455, 1471, 1096 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.38 – 7.28 (m, 5H), 5.93 (dd, J 17.8, 11.0 Hz, 1H), 5.15 (dd, J 11.1, 1.2 Hz, 1H), 5.08 (dd, J 17.8, 1.3 Hz, 1H), 4.52 (d, J 11.9 Hz, 1H), 4.49 (d, J 11.9 Hz, 1H), 3.79 (dd, J 5.4, 3.9 Hz, 1H), 3.62 (dd, J 10.1, 3.8 Hz, 2H), 3.57 – 3.51 (m, 1H), 3.44 (dd, J 10.1, 5.5 Hz, 1H), 2.66 (s, 1H), 1.11 (s, 3H), 0.91 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H) ppm; ^{13}C NMR (126 MHz, $CDCl_3$) δ 141.4, 138.0, 128.5, 127.84, 127.78, 114.8, 77.6, 73.5, 73.0, 68.1, 45.7, 26.1, 19.0, 18.4, -3.9, -4.9 ppm; HRMS calcd for $C_{20}H_{34}O_3SiNa$ [$M+Na^+$]: 373.2169; found 373.2155 (-3.8 ppm).

(+)-(S)-2-((S)-2-(Benzyloxy)-1-[(tert-butyldimethylsilyl)oxy]ethyl)-2-methylbut-3-enal (6): To a solution of primary alcohol **S1** (0.84 g, 2.4 mmol, 1.0 equiv.) in CH_2Cl_2 (24 mL, 0.10 M), Dess-Martin periodinane (DMP, 1.1 g, 2.6 mmol, 1.1 equiv.) was added. The resulting suspension was stirred for 16 hours at room temperature before addition of saturated aqueous $Na_2S_2O_3$ (20 mL). The biphasic mixture was vigorously stirred for 30 minutes. The aqueous layer was extracted with CH_2Cl_2 (1x20 mL), the combined organic fractions were washed with brine, dried over $MgSO_4$, filtered and concentrated *in vacuo*. The crude aldehyde was purified by flash chromatography (Hexanes/ $EtOAc$) to provide **6** as a colorless oil (700 mg, 84% yield): $R_f = 0.59$ (Hexanes/ $EtOAc$, 88:12); $[\alpha]_D^{25} +2.0$ ($c = 3.0$, CH_2Cl_2); Molecular formula: $C_{20}H_{32}O_3Si$; MW: 348.56; IR (neat) ν_{max} 1726 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 9.58 (s, 1H), 7.37 – 7.27 (m, 5H), 6.06 (dd, J 17.8, 10.9 Hz, 1H), 5.29 (d, J 10.9 Hz, 1H), 5.13 (d, J 17.8 Hz, 1H), 4.47 (d, J 11.9 Hz, 1H), 4.43 (d, J 11.9 Hz, 1H), 4.10 (t, J 5.2 Hz, 1H), 3.46 (dd, J 9.9, 5.1 Hz, 1H), 3.42 (dd, J 9.9, 5.4 Hz, 1H), 1.18 (s, 3H), 0.86 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H) ppm; ^{13}C NMR (126 MHz, $CDCl_3$) δ 202.0, 137.9, 137.0, 128.5, 127.83, 127.80, 117.3, 75.5, 73.5, 72.1, 56.9, 26.0, 18.3, 14.6, -4.0, -4.9 ppm; HRMS calcd for $C_{20}H_{32}O_3SiNa$ [$M+Na^+$]: 371.2013; found 371.2000 (-3.5 ppm).

Compounds 5a and 16 from Scheme 5:

(-)-(2R,3R)-3-[(S)-2-(Benzyloxy)-1-[(*tert*-butyldimethylsilyl)oxy]ethyl]-2-hydroxy-3-methylpent-4-enitrile (5a), and (2S,3R)-1-(benzyloxy)-2-[(*tert*-butyldimethylsilyl)oxy]-3-[(S)-cyano(hydroxy)methyl]-3-methylpent-4-en-1-ylum (5b): A solution of aldehyde **6** (700 mg, 2.01 mmol, 1.00 equiv.) in CH₂Cl₂ (20 mL, 0.10 M) was cooled to -15 °C (NH₄Cl/ice) before addition of MgBr₂·OEt₂ (2.6 g, 10 mmol, 5.0 equiv.) in one portion. After 10 minutes, TMSCN (0.50 mL, 4.0 mmol, 2.0 equiv.) was added dropwise and the resulting mixture was stirred 1 hour at -15 °C. The reaction was quenched with saturated aqueous NaHCO₃ (20 mL) and the biphasic mixture warmed to room temperature. After stirring vigorously for 15 minutes, Et₂O (20 mL) was added and the aqueous layer was extracted with Et₂O (1 × 15 mL). The combined organic fractions were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to afford the crude cyanohydrin which could be used directly for the next step. ¹H NMR analysis of the crude mixture showed an 8:1 mixture of stereoisomers. Data for the major 2,4-*syn*-cyanohydrin **5a** ([α]_D²⁵ -1.9 (c= 5.5, CH₂Cl₂)) correspond to that obtained from the reaction of racemic aldehyde **6** with MgBr₂·OEt₂ at 0 °C (Table 1, entry 1) as seen below.

(+)-(2R,3R)-3-[(S)-2-(Benzyloxy)-1-[(*tert*-butyldimethylsilyl)oxy]ethyl]-2-[(*tert*-butyldimethylsilyl)oxy]-3-methylpent-4-enitrile (16): The crude cyanohydrin **5** (755 mg, 2.01 mmol, 1.00 equiv.) was dissolved in CH₂Cl₂ (10 mL, 0.20 M) and the resulting solution was cooled to 0 °C followed by addition of pyridine (0.49 mL, 6.0 mmol, 3.0 equiv.) and TBSOTf (0.55 mL, 2.4 mmol, 1.2 equiv.). The reaction was stirred at 0 °C for 16 hours followed by addition of saturated aqueous NaHCO₃ (15 mL) and hexanes (15 mL). The aqueous layer was extracted with Hexanes/Et₂O (2:1, 2 × 15mL) and the combined organic fractions were washed with 0.1 N HCl followed by brine, dried over MgSO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography (Hexanes/Et₂O) provided the protected cyanohydrin **16** as a single diastereoisomer (815 mg, 83% yield over two steps): R_f = 0.52 (Hexanes/Et₂O, 95:5); [α]_D²⁵ +36 (c= 2.3, CH₂Cl₂); Molecular formula: C₂₇H₄₇NO₃Si₂; MW: 489.85; IR (neat) ν_{max} 2953, 2929, 2857, 1253, 1118, 1102 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.26 (m, 5H), 5.89 (dd, *J* 17.6, 10.9 Hz, 1H), 5.24 (dd, *J* 10.9, 1.0 Hz, 1H), 5.13 (dd, *J* 17.6, 1.2 Hz, 1H), 4.71 (s, 1H), 4.48 (d, *J* 11.9 Hz, 1H), 4.41 (d, *J* 11.9 Hz, 1H), 3.99 (dd, *J* 6.7, 2.5 Hz, 1H), 3.51 (dd, *J* 10.2, 2.6 Hz, 1H), 3.27 (dd, *J* 10.2, 6.7 Hz, 1H), 1.16 (s, 3H), 0.90 (s, 9H), 0.88 (s, 9H), 0.16 (s, 6H), 0.08 (s, 3H), 0.06 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 138.1, 137.3, 128.5, 127.7, 119.2, 117.9, 76.5, 73.4, 73.2, 67.0, 49.5, 26.2, 25.7, 18.5, 18.2, 14.9, -3.8, -5.10, -5.11, -5.3 ppm; HRMS calcd for C₂₇H₄₇NO₃Si₂Na [M+Na⁺]: 512.2987; found 512.2963 (-4.6 ppm).

Aldehydes 17, 19, 21, 23, 25 and 27 along with cyanohydrins 5a,b, 18a,b, 20a,b, 22a,b, 24a,b, 26a,b and 28a,b from Table 1 (racemic):

(±)-(S)-Ethyl 2-[(S)-2-(Benzyloxy)-1-(*tert*-butyldimethylsilyloxy)ethyl]-2-methylbut-3-enoate (S2): To a solution of (*S*)-methyl 2-[(*S*)-2-(benzyloxy)-1-hydroxyethyl]-2-methylbut-3-enoate²² (4.29 g, 16.2 mmol, 1.00 equiv.) in anhydrous CH₂Cl₂ (160 mL, 0.10 M) at 0 °C, 2,6-lutidine (3.8 mL, 33 mmol, 2.0 equiv.) and TBSOTf (5.22 mL, 22.7 mmol, 1.40 equiv.) were added. The solution was stirred until the alcohol was all consumed, 1h30 at 0 °C, as determined by TLC. An aqueous solution of NH₄Cl was added to the reaction mixture and the aqueous layer was extracted with Et₂O (3x). The organic layers were combined, dried over MgSO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography using 5:95 EtOAc:Hex provided protected ester **S2** as a clear oil (5.1 g, 83% yield): R_f = 0.3 (5:95 EtOAc:Hex); Molecular formula: C₂₁H₃₄O₄Si; MW: 378.58; IR (neat) ν_{max} 1737 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.27 (m, 5H), 6.10 (dd, *J* 17.6, 10.8 Hz, 1H), 5.17 (dd, *J* 10.8, 0.9 Hz, 1H), 5.08 (dd, *J* 17.6, 1.0 Hz, 1H), 4.47 (d, *J* 11.8 Hz, 1H), 4.41 (d, *J* 11.8 Hz, 1H), 4.24 (dd, *J* 6.2, 4.8 Hz, 1H), 3.59 (s, 3H), 3.44 (dd, *J* 10.0, 4.8 Hz, 1H), 3.35 (dd, *J* 10.0, 6.2 Hz, 1H), 1.26 (s, 3H), 0.84 (s, 9H), 0.04 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 174.9, 139.5, 138.2, 128.4, 127.8, 127.7, 115.0, 75.7, 73.4, 72.8, 53.5, 52.0, 26.0, 18.3, 15.8, -3.9, -4.9 ppm; HRMS calcd for C₂₁H₃₅O₄Si [M+H⁺]: 379.2299, found 379.2301 (0.6 ppm).

(±)-(R)-2-[(S)-2-(Benzyloxy)-1-(tert-butyldimethylsilyloxy)ethyl]-2-methylbut-3-en-1-ol (S1): Following General Procedure A and purification by flash chromatography using 10:90 EtOAc:Hex, racemic alcohol **S1** (4.5 g, 95% yield) was obtained as a clear oil. ¹H NMR and ¹³C NMR as reported above for enantiopure compound.

(±)-(S)-2-[(S)-2-(Benzyloxy)-1-(tert-butyldimethylsilyloxy)ethyl]-2-methylbut-3-enal (6): Following General Procedure B and purification by flash chromatography using 20:80 EtOAc:Hex, racemic aldehyde **6** (4.4 g, 97% yield) was obtained as a clear oil. ¹H NMR and ¹³C NMR as reported above for enantiopure compound.

(±)-(2R,3R)-3-[(S)-2-(Benzyloxy)-1-(tert-butyldimethylsilyloxy)ethyl]-2-hydroxy-3-methylpent-4-enenitrile (5a) and (±)-(2S,3R)-3-[(S)-2-(benzyloxy)-1-(tert-butyldimethylsilyloxy)ethyl]-2-hydroxy-3-methylpent-4-enenitrile (5b): Cyanohydrins **5a** and **5b** were prepared following General Procedure C. ¹H NMR spectroscopic analysis of the crude reaction indicated a 6:1 mixture of 2,4-*syn* and *anti* diastereomers (Table 1, entry 1). Purification by flash chromatography using 10:90 EtOAc:Hex provided **5a** and **5b** as a clear oil (69.1 mg, 79% yield). **5a**: R_f = 0.15 (10:90 EtOAc:Hex); Molecular formula: C₂₁H₃₃NO₃Si; MW: 375.58; IR (neat) ν_{max} 3447, 2362 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.40 – 7.29 (m, 5H), 6.02 (dd, *J* 17.6, 11.0 Hz, 1H), 5.34 (dd, *J* 11.0, 0.9 Hz, 1H), 5.27 (dd, *J* 17.6, 0.9 Hz, 1H), 4.58 (d, *J* 4.8 Hz, 1H), 4.55 (d, *J* 11.7 Hz, 1H), 4.51 (d, *J* 11.7 Hz, 1H), 4.15 (d, *J* 5.3 Hz, 1H), 3.87 (dd, *J* 5.3, 3.9 Hz, 1H), 3.55 (dd, *J* 10.4, 5.2 Hz, 1H), 3.47 (dd, *J* 10.4, 3.9 Hz, 1H), 1.20 (s, 3H), 0.88 (s, 9H), 0.09 (s, 3H), 0.03 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 137.7, 136.8, 128.7, 128.3, 128.1, 118.8, 118.2, 76.1, 73.8, 71.4, 66.7, 49.1, 26.0, 18.3, 17.0, -4.1, -4.9 ppm; HRMS calcd for C₂₁H₃₄O₃NSi [M+H⁺]: 376.2302, found 376.2303 (0.04 ppm). **5b**: R_f = 0.19 (10:90 EtOAc:Hex); IR (neat) ν_{max} 3424, 2247 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.27 (m, 5H), 5.89 (dd, *J* 17.6, 11.0 Hz, 1H), 5.32 (d, *J* 11.0 Hz, 1H), 5.27 (d, *J* 17.6 Hz, 1H), 4.70 (d, *J* 5.7 Hz, 1H), 4.48 (s, 2H), 3.95 (dd, *J* 4.9, 3.9 Hz, 1H), 3.81 (d, *J* 6.5 Hz, 1H), 3.55 (dd, *J* 10.3, 3.9 Hz, 1H), 3.43 (dd, *J* 10.4, 5.0 Hz, 1H), 1.27 (s, 3H), 0.89 (s, 9H), 0.13 (s, 3H), 0.08 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 137.6, 137.1, 128.6, 128.0, 127.9, 118.9, 118.2, 77.4, 73.5, 72.3, 68.0, 47.6, 26.0, 18.3, 16.5, -4.1, -4.9 ppm; HRMS calcd for C₂₁H₃₄O₃NSi [M+H⁺]: 376.2302, found 376.2302 (-0.2 ppm).

(±)-(S)-Methyl 2-[(S)-1,2-bis(benzyloxy)ethyl]-2-methylbut-3-enoate (S3): To a solution of (S)-methyl 2-[(S)-2-(benzyloxy)-1-hydroxyethyl]-2-methylbut-3-enoate²² (0.32 g, 1.2 mmol, 1.0 equiv.) in a mixture of 2:1 cyclohexane:DCM (6.1 mL, 0.20 M) at 0 °C, benzyl-2,2,2-trichloroacetimidate (340 μL, 1.80 mmol, 1.80 equiv.) and triflic acid (11 μL, 0.12 mmol, 0.10 equiv.) were added. The solution was stirred overnight at 0 °C. Triethylamine (100 μL, 0.61 mmol, 0.50 equiv.) was added and the reaction mixture was then concentrated. Purification by flash chromatography using 15:85 (EtOAc:Hex): provided protected ester **S3** as a clear oil (0.36 g, 84% yield): R_f = 0.28 (15:85 EtOAc:Hex); Molecular formula: C₂₂H₂₆O₄; MW: 354.45; IR (neat) ν_{max} 3030, 2949, 2865, 1734, 1117 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.48 – 7.06 (m, 10H), 6.15 (dd, *J* 17.6, 10.9 Hz, 1H), 5.16 (d, *J* 10.8 Hz, 1H), 5.09 (d, *J* 17.6 Hz, 1H), 4.76 (d, *J* 11.5 Hz, 1H), 4.57 (d, *J* 11.5 Hz, 1H), 4.47 (d, *J* 11.9 Hz, 1H), 4.43 (d, *J* 11.9 Hz, 1H), 4.03 (dd, *J* 6.0, 4.6 Hz, 1H), 3.57 (s, 3H), 3.54 (d, *J* = 6.1 Hz, 1H), 3.53 (d, *J* 4.5 Hz, 1H), 1.28 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 174.9, 138.9, 138.6, 138.3, 128.5, 128.3, 127.72, 127.71, 127.65, 127.5, 115.2, 82.8, 74.2, 73.5, 71.8, 52.9, 52.2, 16.8 ppm; HRMS calcd for C₂₂H₂₇O₄ [M+H⁺]: 355.1904, found: 355.1912 (2.4 ppm).

(±)-(R)-2-[(S)-1,2-Bis(benzyloxy)ethyl]-2-methylbut-3-en-1-ol (S4): Following General Procedure A and purification by flash chromatography using 25:75 EtOAc:Hex, provided primary alcohol **S4** as a clear oil (58.3 mg, 98% yield): R_f = 0.23 (20:80 EtOAc:Hex); Molecular formula: C₂₁H₂₆O₃; MW: 326.44; IR (neat) ν_{max} 3443, 2871, 1091 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.26 (m, 10H), 5.98 (dd, *J* 17.7, 11.0 Hz, 1H), 5.15 (dd, *J* 11.0, 1.3 Hz, 1H), 5.09 (dd, *J* 17.8, 1.2 Hz, 1H), 4.83 (d, *J* 11.5 Hz, 1H), 4.58 (d, *J* 11.5 Hz, 1H), 4.53 (s, 2H), 3.71 (app.q, *J* 5.9 Hz, 1H), 3.61 (app.q, *J* 5.9 Hz, 2H), 3.59 – 3.55 (m, 1H), 3.51 (dd, *J* 10.9, 5.5 Hz, 1H), 2.46 – 2.41 (m, 1H), 1.08 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 140.6, 138.6, 138.2, 128.57, 128.53, 128.0, 127.84, 127.82,

127.76, 115.0, 83.7, 73.6, 73.6, 71.8, 68.8, 45.5, 18.8 ppm; HRMS calcd for C₂₁H₂₆O₃Na [M+Na⁺]: 349.1774, found: 349.1781 (1.9 ppm).

(±)-(S)-2-[(S)-1,2-Bis(benzyloxy)ethyl]-2-methylbut-3-enal (17): Following General Procedure B and purification by flash chromatography using 20:80 EtOAc:Hex, provided aldehyde **17** as a clear oil (1.82 g, 98% yield): R_f = 0.41 (30:70 EtOAc:Hex); Molecular formula: C₂₁H₂₄O₃; MW: 324.42; IR (neat) ν_{max} 2865, 1725, 1095 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 9.54 (s, 1H), 7.38 – 7.27 (m, 10H), 6.10 (dd, *J* 17.8, 10.9 Hz, 1H), 5.32 (dd, *J* 10.9, 0.8 Hz, 1H), 5.16 (dd, *J* 17.8, 0.8 Hz, 1H), 4.77 (d, *J* 11.5 Hz, 1H), 4.58 (d, *J* 11.5 Hz, 1H), 4.49 (s, 2H), 3.88 (t, *J* 4.9 Hz, 1H), 3.61 (app.s, 1H), 3.60 (app.s, 1H), 1.20 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 201.8, 138.4, 138.0, 136.8, 128.6, 128.4, 127.90, 127.86, 127.8 (one aromatic carbon missing), 117.7, 81.8, 73.7, 73.6, 70.4, 56.3, 15.4 ppm; HRMS calcd for C₂₁H₂₄O₃Na [M+Na⁺]: 347.1618, found: 347.1619 (0.4 ppm).

(±)-(2R,3R)-3-[(S)-1,2-Bis(benzyloxy)ethyl]-2-hydroxy-3-methylpent-4-enitrile (18a) and (±)-(2S,3R)-3-[(S)-1,2-bis(benzyloxy)ethyl]-2-hydroxy-3-methylpent-4-enitrile (18b): Cyanohydrins **18a** and **18b** were prepared following General Procedure C. ¹H NMR spectroscopic analysis of the crude reaction indicated an 8:1 mixture of 2,4-*syn* and *anti* diastereomers (Table 1, entry 3). Purification by flash chromatography using 20:80 EtOAc:Hex, provided **18a** and **18b** (44.2 mg, 92% yield) as a clear oil. **18a**: R_f = 0.22 (20:80 EtOAc:Hex); Molecular formula: C₂₂H₂₅NO₃; MW: 351.45; IR (neat) ν_{max} 3419, 2244 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.28 (m, 10H), 6.04 (dd, *J* 17.6, 11.0 Hz, 1H), 5.36 (d, *J* 11.0 Hz, 1H), 5.28 (d, *J* 17.6 Hz, 1H), 4.76 (d, *J* 11.3 Hz, 1H), 4.62 (d, *J* 4.9 Hz, 1H), 4.56 (d, *J* 11.9 Hz, 1H), 4.53 (d, *J* 11.3 Hz, 1H), 4.52 (d, *J* 11.8 Hz, 1H), 3.78 (d, *J* 5.0 Hz, 1H), 3.72 – 3.65 (m, 2H), 3.60 (dd, *J* 10.2, 4.0 Hz, 1H), 1.23 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 137.8, 137.2, 136.9, 128.7, 128.6, 128.3, 128.13, 128.12, 128.0, 118.57, 118.53, 82.6, 73.8, 73.5, 69.8, 67.2, 48.5, 17.1 ppm; HRMS calcd for C₂₂H₂₅O₃NNa [M+Na⁺]: 374.1727, found 374.1730 (0.8 ppm). **18b**: R_f = 0.18 (20:80 EtOAc:Hex); IR (neat) ν_{max} 3420, 2244 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.41 – 7.28 (m, 10H), 6.02 (dd, *J* 17.6, 11.0 Hz, 1H), 5.31 (d, *J* 11.0 Hz, 1H), 5.24 (d, *J* 17.7 Hz, 1H), 4.89 (d, *J* 11.1 Hz, 1H), 4.65 (d, *J* 11.1 Hz, 1H), 4.53 (s, 2H), 4.40 (d, *J* 8.8 Hz, 1H), 3.96 (dd, *J* 5.6, 3.3 Hz, 1H), 3.80 (d, *J* 8.8 Hz, 1H), 3.63 (dd, *J* 10.8, 3.3 Hz, 1H), 3.59 (dd, *J* 10.8, 5.6 Hz, 1H), 1.22 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 137.8, 137.6, 136.0, 128.9, 128.7, 128.5, 128.4, 128.0, 127.8, 118.9, 118.0, 83.1, 73.9, 73.6, 71.6, 69.4, 47.0, 17.2 ppm; HRMS calcd for C₂₂H₂₅O₃NNa [M+Na⁺]: 374.1727, found 374.1730 (0.9 ppm).

(±)-(S)-Methyl 2 [(S)-2-(benzyloxy)-1-(4-methoxybenzyloxy)ethyl]-2-methylbut-3-enoate (S5): To a solution of (S)-methyl 2-[(S)-2-(benzyloxy)-1-hydroxyethyl]-2-methylbut-3-enoate²² (2.0 g, 7.7 mmol, 1.0 equiv.) in dry ether (77 mL, 0.10 M) at 0 °C, 4-methoxybenzyl-2,2,2-trichloroacetimidate (6.5 g, 23 mmol, 3.0 equiv.) and triflic acid (3.4 μL, 0.039 mmol, 0.0050 equiv.) were added. The solution was stirred until the alcohol was all consumed, 1h30 at 0 °C, as determined by TLC. Triethylamine (11 μL, 0.080 mmol, 0.010 equiv.) was added to the reaction at 0 °C. An aqueous solution of NaHCO₃ was added and the aqueous layer was extracted with Et₂O (3x). The organic layers were combined, dried over MgSO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography using 20:80 EtOAc:Hex provided protected ester **S5** as a clear oil (2.09 g, 70% yield): R_f = 0.25 (20:80 EtOAc:Hex); Molecular formula: C₂₃H₂₈O₅; MW: 384.47; IR (neat) ν_{max} 1734 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.27 (m, 5H), 7.23 (d, *J* 8.5 Hz, 2H), 6.86 (d, *J* 8.6 Hz, 2H), 6.17 (dd, *J* 17.6, 10.8 Hz, 1H), 5.20 (d, *J* 10.8 Hz, 1H), 5.13 (d, *J* 17.6 Hz, 1H), 4.72 (d, *J* 11.0 Hz, 1H), 4.55 (d, *J* 11.0 Hz, 1H), 4.52 (d, *J* 11.9 Hz, 1H), 4.48 (d, *J* 11.6 Hz, 1H), 4.05 (dd, *J* 5.9, 4.7 Hz, 1H), 3.80 (s, 3H), 3.62 (s, 3H), 3.60 – 3.53 (m, 2H), 1.32 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 174.9, 159.2, 138.7, 138.3, 131.0, 129.3, 128.5, 127.7, 115.2, 113.7, 82.4, 73.9, 73.5, 71.8, 55.38, 55.36, 52.9, 52.1, 16.7 ppm; HRMS calcd for C₂₃H₂₈O₅Na [M+Na⁺]: 407.1829, found 407.1837 (1.9 ppm).

(±)-(R)-2-[(S)-2-(Benzyloxy)-1-(4-methoxybenzyloxy)ethyl]-2-methylbut-3-en-1-ol (S6): Following General Procedure A and purification by flash chromatography using 20:80 EtOAc:Hex, provided primary alcohol **S6** as

a clear oil (1.1 g, quantitative yield): $R_f = 0.2$ (30:70 EtOAc:Hex); Molecular formula: $C_{22}H_{28}O_4$; MW: 356.46; IR (neat) ν_{max} 3451 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.41 – 7.28 (m, 5H), 7.27 (d, J 8.7 Hz, 2H), 6.88 (d, J 8.6 Hz, 2H), 5.97 (dd, J 17.7, 11.0 Hz, 1H), 5.14 (dd, J 11.0, 1.3 Hz, 1H), 5.08 (dd, J 17.7, 1.3 Hz, 1H), 4.76 (d, J 11.2 Hz, 1H), 4.54 (s, 2H), 4.52 (d, $J = 11.1$ Hz, 1H), 3.81 (s, 3H), 3.72 – 3.67 (m, 1H), 3.63 – 3.53 (m, 3H), 3.48 (dd, J 11.0, 5.5 Hz, 1H), 2.49 (dd, J 7.2, 5.5 Hz, 1H), 1.06 (s, 3H) ppm; ^{13}C NMR (126 MHz, $CDCl_3$) δ 159.4, 140.6, 138.2, 130.6, 129.7, 128.6, 127.8, 127.7, 114.9, 113.9, 83.3, 73.5, 73.2, 71.9, 68.9, 55.4, 45.4, 18.8 ppm; HRMS calcd for $C_{22}H_{28}O_4Na$ [$M+Na^+$]: 379.1880, found 379.1887 (1.8 ppm).

(±)-(S)-2-[(S)-2-(Benzyloxy)-1-(4-methoxybenzyloxy)ethyl]-2-methylbut-3-enal (19): Following General Procedure B and purification by flash chromatography using 15:85 EtOAc:Hex provided aldehyde **19** as a clear oil (1.02 g, 94% yield): $R_f = 0.2$ (30:70 EtOAc:Hex); Molecular formula: $C_{22}H_{26}O_4$; MW: 354.45; IR (neat) ν_{max} 1726 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 9.55 (s, 1H), 7.41 – 7.29 (m, 5H), 7.25 (d, J 8.5 Hz, 2H), 6.89 (d, J 8.5 Hz, 2H), 6.11 (dd, J 17.8, 10.9 Hz, 1H), 5.33 (d, J 10.9 Hz, 1H), 5.18 (d, J 17.7 Hz, 1H), 4.72 (d, J 11.2 Hz, 1H), 4.54 (d, J 11.3 Hz, 1H), 4.52 (s, 2H), 3.89 (t, J 4.9 Hz, 1H), 3.82 (s, 3H), 3.62 (d, J 4.9 Hz, 2H), 1.22 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 201.8, 159.3, 137.9, 136.5, 130.3, 129.6, 128.5, 127.8, 127.7, 117.5, 113.8, 81.2, 73.4, 73.2, 70.3, 56.2, 55.3, 15.3 ppm; HRMS calcd for $C_{22}H_{26}O_4Na$ [$M+Na^+$]: 377.1723, found 377.1726 (0.7 ppm).

(±)-(2R,3R)-3-[(S)-2-(Benzyloxy)-1-(4-methoxybenzyloxy)ethyl]-2-hydroxy-3-methylpent-4-enitrile (20a) and (±)-(2S,3R)-3-[(S)-2-(benzyloxy)-1-(4-methoxybenzyloxy)ethyl]-2-hydroxy-3-methylpent-4-enitrile (20b): Cyanohydrins **20a** and **20b** were prepared following General Procedure C. 1H NMR spectroscopic analysis of the crude reaction indicated an 8:1 mixture of 2,4-*syn* and *anti* diastereomers (Table 1, entry 4). Purification by flash chromatography using 25:75 EtOAc:Hex provided **20a** and **20b** (47.9 mg, 93% yield) as a clear oil. **20a**: $R_f = 0.13$ (25:75 EtOAc:Hex); Molecular formula: $C_{23}H_{27}NO_4$; MW: 381.47; IR (neat) ν_{max} 3431, 2247 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.40 – 7.30 (m, 5H), 7.23 (d, J 8.7 Hz, 2H), 6.87 (d, J 8.7 Hz, 2H), 6.03 (dd, J 17.6, 11.0 Hz, 1H), 5.35 (dd, J 11.0, 0.9 Hz, 1H), 5.27 (dd, J 17.6, 0.9 Hz, 1H), 4.68 (d, J 11.0 Hz, 1H), 4.58 (d, J 5.0 Hz, 1H), 4.55 (s, 1H), 4.54 (s, 1H), 4.46 (d, J 11.0 Hz, 1H), 3.84 (d, J 5.0 Hz, 1H), 3.81 (s, 3H), 3.69 – 3.64 (m, 2H), 3.61 – 3.56 (m, 1H), 1.20 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 159.6, 137.3, 136.9, 129.9, 129.8, 128.7, 128.2, 128.0, 118.6, 118.5, 114.0, 82.3, 73.8, 73.2, 69.9, 67.4, 55.4, 48.4, 17.2 ppm; HRMS calcd for $C_{23}H_{27}NO_4Na$ [$M+Na^+$]: 404.1832, found 404.1826 (-1.5 ppm). **20b**: $R_f = 0.17$ (25:75 EtOAc:Hex); IR (neat) ν_{max} 3421, 2244 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.41 – 7.30 (m, 5H), 7.29 (d, J 8.5 Hz, 2H), 6.89 (d, J 8.6 Hz, 2H), 6.01 (dd, J 17.6, 11.0 Hz, 1H), 5.30 (d, J 11.0 Hz, 1H), 5.23 (d, J 17.6 Hz, 1H), 4.82 (d, J 10.8 Hz, 1H), 4.58 (d, J 10.8 Hz, 1H), 4.54 (s, 2H), 4.38 (app.dd, J 8.8, 2.1 Hz, 1H), 3.95 (dd, J 5.7, 3.3 Hz, 1H), 3.92 (app.dd, J 8.8, 2.8 Hz, 1H), 3.81 (s, 3H), 3.62 (dd, J 10.8, 3.4 Hz, 1H), 3.58 (dd, J 10.8, 5.6 Hz, 1H), 1.21 (s, 3H) ppm; ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 159.7, 137.9, 136.0, 130.3, 129.6, 128.6, 128.0, 127.7, 119.0, 117.9, 114.2, 82.8, 73.6, 73.5, 71.7, 69.5, 55.4, 46.9, 17.3 ppm; HRMS calcd for $C_{23}H_{27}NO_4Na$ [$M+Na^+$]: 404.1832, found 404.1827 (-1.2 ppm).

(±)-(S)-2-[(S)-2-(Benzyloxy)-1-hydroxyethyl]-2-methylbut-3-enal (21): To a solution of racemic aldehyde **6** (0.14 g, 0.42 mmol, 1.0 equiv.) in dry THF (4.1 μ L, 0.10 M) at 0 °C, HF-pyridine (0.84 mL, 0.84 mmol, 2.0 mL/mmol) was added. The solution was warmed to room temperature and stirred overnight. An aqueous solution of $NaHCO_3$ was added and the aqueous layer was extracted with Et_2O (3x). The organic layers were combined, dried with $MgSO_4$, filtered and concentrated *in vacuo*. Purification by flash chromatography using 30:70 EtOAc:Hex provided aldehyde **21** as a clear oil (56.6 mg, 58% yield): $R_f = 0.23$ (30:70 EtOAc:Hex); Molecular formula: $C_{14}H_{18}O_3$; MW: 234.30; IR (neat) ν_{max} 3460, 1725 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 9.53 (s, 1H), 7.38 – 7.28 (m, 5H), 6.07 (dd, J 17.7, 10.9 Hz, 1H), 5.39 (d, J 10.9 Hz, 1H), 5.21 (d, J 17.8 Hz, 1H), 4.53 (s, 2H), 4.08 (dd, J 7.3, 3.7 Hz, 1H), 3.54 (dd, J 9.8, 3.7 Hz, 1H), 3.48 (dd, J 9.8, 7.4 Hz, 1H), 2.63 (s, 1H), 1.21 (s, 3H) ppm; ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 202.3, 137.7, 135.5, 128.5, 127.9, 127.8, 118.4, 73.8, 73.5, 70.7, 55.7, 15.1 ppm; HRMS for $C_{14}H_{18}O_3Na$ [$M+Na^+$]: 257.1148, found 257.1146 (-0.9 ppm).

(±)-(2R,3R)-3-[(S)-2-(benzyloxy)-1-hydroxyethyl]-2-hydroxy-3-methylpent-4-enitrile (22a) and (±)-(2S,3R)-3-[(S)-2-(benzyloxy)-1-hydroxyethyl]-2-hydroxy-3-methylpent-4-enitrile (22b): Cyanohydrins **22a** and **22b** were prepared following General Procedure C. ¹H NMR spectroscopic analysis of the crude reaction indicated a 1:4 mixture of 2,4-*syn* and *anti* diastereomers (Table 1, entry 5). Purification by flash chromatography using 50:50 EtOAc:Hex provided **22a** and **22b** (26 mg, 89% yield). **22a**: *R_f* = 0.33 (50:50 EtOAc:Hex); Molecular formula: C₁₅H₁₉NO₃; MW: 261.32; IR (neat) *v*_{max} 3428, 2246 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.41 – 7.29 (m, 5H), 6.11 (dd, *J* 17.7, 11.0 Hz, 1H), 5.43 (dd, *J* 11.0, 0.8 Hz, 1H), 5.30 (dd, *J* 17.7, 0.9 Hz, 1H), 4.66 (d, *J* 4.5 Hz, 1H), 4.57 (d, *J* 11.7 Hz, 1H), 4.54 (d, *J* 11.7 Hz, 1H), 3.97 (ddd, *J* 8.1, 3.9, 2.3 Hz, 1H), 3.72 (d, *J* 4.5, 1H), 3.58 (dd, *J* 9.7, 3.8 Hz, 1H), 3.46 (dd, *J* 9.7, 8.1 Hz, 1H), 2.76 (d, *J* 2.3 Hz, 1H), 1.17 (s, 3H) ppm; ¹³C NMR (100.6 MHz, CDCl₃) δ 137.2, 135.6, 128.8, 128.4, 128.0, 119.2, 118.2, 75.0, 73.8, 70.4, 68.4, 46.9, 16.1 ppm; HRMS for C₁₅H₂₀O₃N [M+H⁺]: 262.1438, found 262.1438 (0.3 ppm). **22b**: *R_f* = 0.29 (50:50 EtOAc:Hex); IR (neat) *v*_{max} 3423, 2246 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.42 – 7.28 (m, 5H), 6.15 (dd, *J* 17.7, 11.0 Hz, 1H), 5.35 (d, *J* 11.0 Hz, 1H), 5.25 (dd, *J* 17.7, 0.8 Hz, 1H), 4.54 (s, 2H), 4.41 (d, *J* 8.0 Hz, 1H), 4.33 (d, *J* 9.0 Hz, 1H), 4.22 (dd, *J* 9.1, 2.9 Hz, 1H), 3.53 (dd, *J* 9.6, 3.0 Hz, 1H), 3.37 (app.t, *J* 9.3 Hz, 1H), 3.03 (s, 1H), 1.15 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 137.4, 135.7, 128.8, 128.2, 127.9, 118.7, 117.9, 74.6, 73.7, 70.6, 70.5, 45.4, 16.7 ppm; HRMS for C₁₅H₁₉O₃NNa [M+Na⁺]: 284.1257, found 284.1260 (0.9 ppm).

(±)-(S)-Methyl 2-((S)-2,2,3,3,9,9-hexamethyl-8,8-diphenyl-4,7-dioxa-3,8-disiladecan-5-yl)-2-methylbut-3-enoate (S7): To a solution of (*S*)-methyl 2-((*S*)-2-((*tert*-butyldiphenylsilyloxy)-1-hydroxyethyl)-2-methylbut-3-enoate²² (1.0 g, 2.5 mmol, 1.0 equiv.) in anhydrous CH₂Cl₂ (25 mL, 0.10 M) at 0 °C, 2,6-lutidine (0.59 mL, 5.1 mmol, 2.0 equiv.) and TBSOTf (0.84 mL, 3.5 mmol, 1.4 equiv.) were added. The solution was stirred until the alcohol was consumed, 4 hours at 0 °C, as determined by TLC. An aqueous solution of NH₄Cl was added and the aqueous layer was extracted with Et₂O (3×). The organic layers were combined, dried over MgSO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography using 5:95 EtOAc:Hex provided protected ester **S7** as a clear oil (1.02 g, 76% yield): *R_f* = 0.35 (5:95 EtOAc:Hex); Molecular formula: C₃₀H₄₆O₄Si₂; MW: 526.86; IR (neat) *v*_{max} 1737 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.68 – 7.62 (m, 4H), 7.45 – 7.35 (m, 6H), 6.09 (dd, *J* 17.7, 10.8 Hz, 1H), 5.14 (dd, *J* 10.8, 1.0 Hz, 1H), 5.04 (dd, *J* 17.7, 1.1 Hz, 1H), 4.19 (t, *J* 5.5 Hz, 1H), 3.57 (s, 3H), 3.55-3.59 (m, 1H), 3.47 (dd, *J* 10.9, 5.2 Hz, 1H), 1.25 (s, 3H), 1.04 (s, 9H), 0.79 (s, 9H), 0.02 (s, 3H), -0.08 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 175.1, 139.2, 135.84, 135.79, 133.4, 133.3, 129.84, 129.82, 127.815, 127.807, 114.9, 77.6, 66.4, 53.8, 52.0, 27.2, 25.9, 19.3, 18.2, 16.3, -3.9, -5.0 ppm; HRMS calcd for C₃₀H₄₇O₄Si₂ [M+H⁺]: 527.3007, found 527.3010 (0.6 ppm).

(±)-(R)-2-((S)-2,2,3,3,9,9-Hexamethyl-8,8-diphenyl-4,7-dioxa-3,8-disiladecan-5-yl)-2-methylbut-3-en-1-ol (S8): Following General Procedure A and purification by flash chromatography using 5:95 EtOAc:Hex, primary alcohol **S8** was obtained as a clear oil (0.73 g, 97% yield): *R_f* = 0.24 (5:95 EtOAc:Hex); Molecular formula: C₂₉H₄₆O₃Si₂; MW: 498.85; IR (neat) *v*_{max} 3454, 2955, 2932, 1111 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.69 – 7.63 (m, 4H), 7.48 – 7.35 (m, 6H), 5.84 (dd, *J* 17.7, 11.0 Hz, 1H), 5.05 (dd, *J* 11.0, 1.3 Hz, 1H), 5.00 (dd, *J* 17.7, 1.4 Hz, 1H), 3.73 (dd, *J* 10.9, 5.5 Hz, 1H), 3.67 (dd, *J* 5.6, 4.2 Hz, 1H), 3.65 – 3.62 (m, 1H), 3.54 (dd, *J* 10.8, 4.0 Hz, 1H), 3.49 (dd, *J* 10.9, 6.2 Hz, 1H), 2.65 (t, *J* 6.3 Hz, 1H), 1.06 (s, 9H), 1.05 (s, 3H), 0.83 (s, 9H), 0.04 (s, 3H), -0.11 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 141.7, 135.92, 135.85, 133.1, 133.0, 129.952, 129.951, 127.88, 127.85, 114.5, 79.1, 68.3, 66.5, 46.2, 27.0, 26.0, 19.2, 18.247, 18.246, -4.0, -4.9 ppm; HRMS calcd for C₂₉H₄₇O₃Si₂ [M+H⁺]: 499.3058, found 499.3062 (0.7 ppm).

(±)-(S)-2-((S)-2,2,3,3,9,9-hexamethyl-8,8-diphenyl-4,7-dioxa-3,8-disiladecan-5-yl)-2-methylbut-3-enal (23): Following General Procedure B and purification by flash chromatography using 5:95 EtOAc:Hex provided aldehyde **21** as a clear oil (0.53 g, 75% yield): *R_f* = 0.30 (5:95 EtOAc:Hex); Molecular formula: C₂₉H₄₄O₃Si₂; MW: 496.84; IR (neat) *v*_{max} 1727 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 9.68 (s, 1H), 7.38-7.67 (m, 10H), 6.06 (dd, *J* 10.9,

17.6 Hz, 1H), 5.29 (dd, *J* 0.7, 11.0 Hz, 1H), 5.14 (dd, *J* 0.7, 17.8 Hz, 1H), 4.01 (dd, *J* 4.5, 6.5 Hz, 1H), 3.58 (dd, *J* 6.6, 10.7 Hz, 1H), 3.53 (dd, *J* 4.5, 10.9 Hz, 1H), 1.20 (s, 3H), 1.04 (s, 9H), 0.81 (s, 9H), 0.01 (s, 3H), -0.15 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 201.7, 137.3, 135.83, 135.79, 133.0, 132.9, 129.96, 129.95, 127.89, 127.87, 117.1, 76.7, 65.5, 56.9, 26.9, 25.9, 19.2, 18.2, 14.4, -4.1, -4.9 ppm; HRMS calcd for C₂₉H₄₄O₃Si₂Na [M+Na⁺]: 519.2721, found 519.2724 (0.5 ppm).

(±)-(2R,3R)-3-((S)-2,2,3,3,9,9-hexamethyl-8,8-diphenyl-4,7-dioxa-3,8-disiladecan-5-yl)-2-hydroxy-3-methylpent-4-enitrile (24a) and **(±)-(2S,3R)-3-((S)-2,2,3,3,9,9-hexamethyl-8,8-diphenyl-4,7-dioxa-3,8-disiladecan-5-yl)-2-hydroxy-3-methylpent-4-enitrile (24b)**: Cyanohydrins **24a** and **24b** were prepared following General Procedure C. ¹H NMR spectroscopic analysis of the crude reaction indicated a 1.5:1 mixture of 2,4-*syn* and *anti* diastereomers (Table 1, entry 6). Purification by flash chromatography using 25:75 *i*Pr₂O:Hex provided **24a** and **24b** (67 mg, 93% yield) as clear oils. **24a**: *R*_f = 0.29 (25:75 *i*Pr₂O:Hex); Molecular formula: C₃₀H₄₅NO₃Si₂; MW: 523.86; IR (neat) *v*_{max} 3448, 2249 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.72 – 7.62 (m, 4H), 7.52 – 7.36 (m, 6H), 5.98 (dd, *J* 17.6, 11.0 Hz, 1H), 5.30 (dd, *J* 10.9, 0.9 Hz, 1H), 5.23 (dd, *J* 17.6, 0.9 Hz, 1H), 4.53 (d, *J* 6.6 Hz, 1H), 4.25 (d, *J* 6.6 Hz, 1H), 3.87 (dd, *J* 6.9, 3.6 Hz, 1H), 3.64 (dd, *J* 11.3, 6.9 Hz, 1H), 3.52 (dd, *J* 11.3, 3.6 Hz, 1H), 1.16 (s, 3H), 1.08 (s, 9H), 0.78 (s, 9H), 0.01 (s, 3H), -0.25 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 138.4, 135.90, 135.88, 132.13, 132.09, 130.34, 130.30, 128.11, 128.08, 118.8, 118.0, 76.7, 67.1, 65.6, 49.5, 27.0, 26.0, 19.2, 18.2, 15.3, -4.2, -5.0 ppm; HRMS calcd for C₃₀H₄₆NO₃Si₂ [M+H⁺]: 524.3011, found 524.3011 (0.07 ppm). **24b**: *R*_f = 0.21 (25:75 *i*Pr₂O:Hex); IR (neat) *v*_{max} 3423, 2247 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.67 – 7.61 (m, 4H), 7.49 – 7.35 (m, 6H), 5.83 (dd, *J* 17.6, 11.0 Hz, 1H), 5.28 (dd, *J* 10.9, 0.8 Hz, 1H), 5.22 (dd, *J* 17.6, 0.8 Hz, 1H), 4.77 (d, *J* 6.2 Hz, 1H), 3.83 (dd, *J* 5.5, 3.9 Hz, 1H), 3.79 (d, *J* 6.2 Hz, 1H), 3.66 (dd, *J* 11.3, 5.5 Hz, 1H), 3.58 (dd, *J* 11.3, 3.9 Hz, 1H), 1.22 (s, 3H), 1.07 (s, 9H), 0.84 (s, 9H), 0.09 (s, 3H), -0.09 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 137.0, 135.93, 135.85, 132.8, 132.7, 130.13, 130.12, 128.00, 127.95, 118.9, 118.4, 78.4, 68.2, 66.0, 47.9, 27.0, 26.0, 19.2, 18.2, 16.2, -4.2, -5.0 ppm; HRMS calcd for C₃₀H₄₆NO₃Si₂ [M+H⁺]: 524.3011, found 524.3007 (-0.8 ppm).

(±)-(R)-Methyl 3-hydroxy-2,2-dimethyl-6-phenylhexanoate (S9): To a solution of 4-phenylbutanal⁴³ (2.4 g, 16 mmol, 1.0 equiv.) in anhydrous CH₂Cl₂ (160 ml, 0.10 M) at -40 °C, BF₃·OEt₂ (3.0 ml, 24 mmol, 1.5 equiv.) was added. A solution of the commercially available enoxysilane ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane (6.5 ml, 32 mmol, 2.0 equiv.) in CH₂Cl₂ was immediately added at the same temperature. The resulting solution was stirred until the aldehyde was completely consumed as indicated by TLC (one hour). A saturated aqueous solution of NH₄Cl was added and the aqueous layer was extracted with Et₂O (3×). The organic layers were combined, washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography using 25:75 EtOAc:Hex provided ester **S9** as a clear oil (quantitative yield after 2 steps, 4.0 g): *R*_f = 0.25 (25:75 EtOAc:Hex); Molecular formula: C₁₅H₂₂O₃; MW: 250.34; IR (neat) *v*_{max} 3496, 1729 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.32 – 7.14 (m, 5H), 3.69 (s, 3H), 3.64 (ddd, *J* 10.6, 6.9, 2.1 Hz, 1H), 2.65 (m, 2H), 2.41 (d, *J* 6.9 Hz, 1H), 2.04 – 1.88 (m, 1H), 1.75 – 1.61 (m, 1H), 1.49 (m, 1H), 1.39 – 1.28 (m, 1H), 1.18 (s, 3H), 1.16 (s, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 178.6, 142.7, 128.7, 128.6, 126.0, 76.8, 52.3, 47.5, 36.0, 31.5, 28.7, 22.7, 20.7; HRMS calcd for C₁₅H₂₂O₃Na [M+Na⁺]: 273.1461, found 273.1458 (-1.1 ppm).

(±)-(R)-Methyl 3-(tert-butyldimethylsilyloxy)-2,2-dimethyl-6-phenylhexanoate (S10): To a solution of secondary alcohol **S9** (0.88 g, 3.5 mmol, 1.0 equiv.) in anhydrous CH₂Cl₂ (35 mL, 0.10 M) at 0 °C, pyridine (0.56 mL, 7.0 mmol, 2.0 equiv.) and TBSOTf (1.1 mL, 4.9 mmol, 1.4 equiv.) were added. The solution was stirred until the alcohol was consumed, 2.5 hours at 0 °C, as determined by TLC. An aqueous solution of NH₄Cl was added and the aqueous layer extracted with Et₂O (3×). The organic layers were combined, dried over MgSO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography using 5:95 EtOAc:Hex provided protected

ester **S10**: $R_f = 0.25$ (5:95 EtOAc:Hex); Molecular formula: $C_{21}H_{36}O_3Si$; MW: 364.60; IR (neat) ν_{max} 1735 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.34 – 7.27 (m, 2H), 7.24 – 7.17 (m, 3H), 3.97 (dd, J 6.5, 4.1 Hz, 1H), 3.65 (s, 3H), 2.72 – 2.52 (m, 2H), 1.90 – 1.78 (m, 1H), 1.68 – 1.56 (m, 1H), 1.55 – 1.42 (m, 2H), 1.22 (s, 3H), 1.13 (s, 3H), 0.94 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H) ppm; ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 177.8, 142.4, 128.6, 128.5, 126., 77.2, 51.8, 48.6, 36.4, 33.9, 29.1, 26.3, 22.4, 20.2, 18.6, -3.4, -4.0 ppm; HRMS for $C_{21}H_{37}O_3Si$ [$M+H^+$]: 365.2506, found 365.2508 (0.4 ppm).

(±)-(R)-3-(tert-Butyldimethylsilyloxy)-2,2-dimethyl-6-phenylhexan-1-ol (S11): Following General Procedure A and purification by flash chromatography using 10:90 EtOAc:Hex, primary alcohol **S11** was obtained as a clear oil (0.7 g, 60% yield over two steps): $R_f = 0.2$ (10:90 EtOAc:Hex); Molecular formula: $C_{20}H_{36}O_2Si$; MW: 336.59; IR (neat) ν_{max} 3443, 2929, 2857, 1472 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.31 – 7.25 (m, 2H), 7.22 – 7.11 (m, 3H), 3.71 (dd, J 10.8, 3.0 Hz, 1H), 3.51 (dd, J 6.0, 3.8 Hz, 1H), 3.25 (dd, J 10.7, 7.6 Hz, 1H), 2.86 (dd, J 7.6, 3.1 Hz, 1H), 2.68 – 2.54 (m, 2H), 1.90 – 1.80 (m, 1H), 1.79 – 1.65 (m, 1H), 1.67 – 1.59 (m, 1H), 1.58 – 1.47 (m, 1H), 1.03 (s, 3H), 0.91 (s, 9H), 0.77 (s, 3H), 0.10 (s, 3H), 0.05 (s, 3H) ppm; ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 142.3, 128.5, 128.4, 125.9, 80.9, 70.4, 39.5, 36.5, 33.3, 29.4, 26.2, 23.9, 21.9, 18.3, -3.7, -4.1 ppm; HRMS for $C_{20}H_{37}O_2Si$ [$M+H^+$]: 337.2557, found 337.2561 (1.0 ppm).

(±)-(R)-3-(tert-Butyldimethylsilyloxy)-2,2-dimethyl-6-phenylhexanal (25): Following General Procedure B and purification by flash chromatography using 5:95 EtOAc:Hex provided aldehyde **25** as a clear oil (0.69 g, 99% yield): $R_f = 0.21$ (5:95 EtOAc:Hex); Molecular formula: $C_{20}H_{34}O_2Si$; MW: 334.58; IR (neat) ν_{max} 1728 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 9.62 (s, 1H), 7.32 – 7.25 (m, 2H), 7.23 – 7.13 (m, 3H), 3.80 – 3.77 (m, 1H), 2.67 – 2.53 (m, 2H), 1.82 – 1.71 (m, 1H), 1.67 – 1.58 (m, 1H), 1.58 – 1.45 (m, 2H), 1.05 (s, 3H), 1.02 (s, 3H), 0.90 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H) ppm; ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 206.7, 142.0, 128.44, 128.43, 125.9, 76.8, 51.4, 36.3, 33.3, 28.3, 26.0, 19.6, 18.3, 17.9, -3.6, -4.2 ppm; HRMS for $C_{20}H_{33}O_2Si$ [$M-H^+$]: 333.2255, found 333.2248 (1.2 ppm).

(±)-(2R,4R)-4-(tert-Butyldimethylsilyloxy)-2-hydroxy-3,3-dimethyl-7-phenylheptanenitrile (26a) and **(±)-(2S,4R)-4-(tert-butylidimethylsilyloxy)-2-hydroxy-3,3-dimethyl-7-phenylheptanenitrile (26b)**: Cyanohydrins **26a** and **26b** were prepared following General Procedure C. 1H NMR spectroscopic analysis of the crude reaction indicated a 2.5:1 mixture of 2,4-*syn* and *anti* diastereomers (Table 1, entry 7). Purification by flash chromatography using 5:95 EtOAc:Hex provided **26a** and **26b** (63 mg, 82% yield) as a clear oil. **26a**: $R_f = 0.28$ (15:85 EtOAc:Hex); Molecular formula: $C_{21}H_{35}NO_2Si$; MW: 361.60; IR (neat) ν_{max} 3446, 2246 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.31 – 7.27 (m, 2H), 7.22 – 7.14 (m, 3H), 4.40 (d, J 6.5 Hz, 1H), 3.60 (dd, J 5.7, 3.3 Hz, 1H), 3.34 (d, J 6.4 Hz, 1H), 2.68 – 2.55 (m, 2H), 1.90 – 1.78 (m, 2H), 1.70 – 1.48 (m, 2H), 1.05 (s, 3H), 1.04 (s, 3H), 0.89 (s, 9H), 0.11 (s, 3H), 0.06 (s, 3H) ppm; ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 142.0, 128.5, 126.0, (one aromatic carbon missing), 119.3, 79.8, 69.2, 42.7, 36.3, 33.6, 29.8, 26.1, 22.0, 19.0, 18.4, -3.7, -4.2 ppm; HRMS for $C_{21}H_{36}O_2NSi$ [$M+H^+$]: 362.2510, found 362.2513 (0.8 ppm). **26b**: $R_f = 0.34$ (15:85 EtOAc:Hex); IR (neat) ν_{max} 3435, 2245 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.31 – 7.27 (m, 2H), 7.22 – 7.14 (m, 3H), 4.51 (d, J 4.0 Hz, 1H), 4.24 (d, J 4.1 Hz, 1H), 3.69 (dd, J 5.5, 4.0 Hz, 1H), 2.69 – 2.51 (m, 2H), 1.90 – 1.78 (m, 1H), 1.75 – 1.58 (m, 2H), 1.54 – 1.43 (m, 1H), 1.15 (s, 3H), 0.98 (s, 3H), 0.89 (s, 9H), 0.13 (s, 3H), 0.07 (s, 3H) ppm; ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 141.7, 128.6, 128.5, 126.2, 119.0, 80.3, 69.6, 41.7, 36.3, 33.1, 29.4, 26.1, 21.6, 20.7, 18.3, -3.8, -4.2 ppm; HRMS for $C_{21}H_{36}O_2NSi$ [$M+H^+$]: 362.2510, found 362.2513 (0.9 ppm).

(±)-(S)-Methyl 4-(benzyloxy)-3-hydroxy-2,2-dimethylbutanoate (S12): To a solution of crude 2-(benzyloxy)-acetaldehyde⁴⁴ (1.8 g, 12 mmol, 1.0 equiv.) in anhydrous CH_2Cl_2 (125 mL, 0.10 M) at -78 °C, $TiCl_4$ (1.00 M, 13.8 mL, 13.8 mmol, 1.15 equiv.) and commercially available enoxysilane ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane (4.9 mL, 24 mmol, 2.0 equiv.) were added. The resulting solution was stirred until the aldehyde was completely consumed as indicated by TLC (generally 90 min). A saturated aqueous solution of

NH₄Cl was added and the aqueous layer was extracted with EtOAc (3×). The organic layers were combined, washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. Purification provided **S12** (2.22 g, 73%) which has been previously reported in the literature.⁴⁵

(±)-(S)-Methyl 4-(benzyloxy)-3-(tert-butyldimethylsilyloxy)-2,2-dimethylbutanoate (S13): To a solution of alcohol **S12** (2.2 g, 8.8 mmol, 1.0 equiv.) in anhydrous CH₂Cl₂ (87 mL, 0.10 M) at 0 °C, 2,6-lutidine (2.0 mL, 18 mmol, 2.0 equiv.) and TBSOTf (2.8 mL, 12 mmol, 1.4 equiv.) were added. The solution was stirred until the alcohol was all consumed (1h 30m). An aqueous solution of NH₄Cl was added and the aqueous layer was extracted with Et₂O (3×). The organic layers were combined, dried over MgSO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography using 5:95 EtOAc:Hex provided protected ester **S13** as a clear oil (2.7 g, 85% yield): R_f = 0.32 (10:90 EtOAc:Hex); Molecular formula: C₂₀H₃₄O₄Si; MW: 366.57; IR (neat) ν_{max} 2953, 2857, 1736, 1468 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.24 (m, 5H), 4.48 (d, *J* 11.8 Hz, 1H), 4.42 (d, *J* 11.8 Hz, 1H), 4.14 (appt, *J* 5.6 Hz, 1H), 3.57 (s, 3H), 3.45 (dd, *J* 9.9, 5.0 Hz, 1H), 3.38 (dd, *J* 9.9, 6.2 Hz, 1H), 1.18 (s, 3H), 1.12 (s, 3H), 0.87 (s, 9H), 0.07 (s, 6H) ppm; ¹³C NMR (100.6 MHz, CDCl₃) δ 177.2, 138.2, 128.4, 127.8, 127.6, 75.5, 73.4, 72.6, 51.7, 46.7, 26.0, 22.7, 19.4, 18.3, -3.9, -5.0 ppm; HRMS calcd for C₂₀H₃₅O₄Si [M+H⁺]: 367.2299, found 367.2293 (-1.7 ppm).

(±)-(S)-4-(Benzyloxy)-3-(tert-butyldimethylsilyloxy)-2,2-dimethylbutan-1-ol (S14): Following General Procedure A and purification by flash chromatography using 25:75 EtOAc:Hex, provided alcohol **S14** as a clear oil (2.1 g, 82% yield): R_f = 0.32 (25:75 EtOAc:Hex); Molecular formula: C₁₉H₃₄O₃Si; MW: 338.56; IR (neat) ν_{max} 3449, 2956, 2930, 2858, 1471, 1095 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.26 (m, 5H), 4.51 (s, 2H), 3.67 (t, *J* 4.6 Hz, 1H), 3.63 (dd, *J* 9.9, 4.6 Hz, 1H), 3.49 – 3.38 (m, 3H), 3.14 (t, *J* 6.0 Hz, 1H), 0.96 (s, 3H), 0.89 (s, 9H), 0.88 (s, 3H), 0.08 (s, 3H), 0.05 (s, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 137.8, 128.5, 127.88, 127.86, 78.5, 73.6, 72.4, 69.9, 39.3, 26.1, 22.5, 22.3, 18.3, -4.0, -4.9 ppm; HRMS calcd for C₁₉H₃₅O₃Si [M+H⁺]: 339.2350, found 339.2347 (-0.8 ppm).

(±)-(S)-4-(Benzyloxy)-3-(tert-butyldimethylsilyloxy)-2,2-dimethylbutanal (27): Following General Procedure B and purification by flash chromatography using 10:90 EtOAc:Hex provided aldehyde **27** as a clear oil (1.9 g, 91% yield): R_f = 0.31 (10:90 EtOAc:Hex); Molecular formula: C₁₉H₃₂O₃Si; MW: 336.55; IR (neat) ν_{max} 1727 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 9.59 (s, 1H), 7.37 – 7.26 (m, 5H), 4.47 (d, *J* 12.2 Hz, 1H), 4.44 (d, *J* 12.0 Hz, 1H), 3.95 (t, *J* 5.3 Hz, 1H), 3.45 (dd, *J* 9.6, 5.1 Hz, 1H), 3.42 (dd, *J* 9.6, 5.0 Hz, 1H), 1.05 (s, 6H), 0.87 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 205.0, 137.9, 128.5, 127.82, 127.79, 75.5, 73.5, 71.8, 50.1, 26.0, 19.1, 18.3, 17.9, -4.0, -4.9 ppm; HRMS calcd for C₁₉H₃₁O₃Si [M+H⁺]: 335.2048, found 335.2033 (-1.2 ppm).

(±)-(2R,4S)-5-(Benzyloxy)-4-(tert-butyldimethylsilyloxy)-2-hydroxy-3,3-dimethylpentanenitrile (28a) and **(±)-(2S,4S)-5-(benzyloxy)-4-(tert-butyldimethylsilyloxy)-2-hydroxy-3,3-dimethylpentanenitrile (28b)**: Cyanohydrins **28a** and **28b** were prepared following General Procedure C. ¹H NMR spectroscopic analysis of the crude reaction indicated an 11:1 mixture of 2,4-*syn* and *anti* diastereomers (Table 1, entry 8). Purification by flash chromatography using 15:85 EtOAc:Hex provided **28a** and **28b** (36.9 mg, 79% yield) as a clear oil. **28a**: R_f = 0.38 (20:80 EtOAc:Hex); Molecular formula: C₂₀H₃₃NO₃Si; MW: 363.57; IR (neat) ν_{max} 3442, 2247 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.40 – 7.29 (m, 5H), 4.78 (d, *J* 6.3 Hz, 1H), 4.56 (s, 2H), 4.47 (d, *J* 5.7 Hz, 1H), 3.74 (dd, *J* 6.0, 3.3 Hz, 1H), 3.57 (dd, *J* 10.5, 6.1 Hz, 1H), 3.50 (dd, *J* 10.5, 3.3 Hz, 1H), 1.09 (s, 3H), 1.07 (s, 3H), 0.88 (s, 9H), 0.08 (s, 3H), 0.02 (s, 3H) ppm; ¹³C NMR (100.6 MHz, CDCl₃) δ 136.5, 128.8, 128.5, 128.2, 119.4, 76.2, 74.0, 70.7, 67.7, 42.9, 25.9, 21.5, 20.9, 18.2, -4.1, -4.9 ppm; HRMS for C₂₀H₃₄O₃NSi [M+H⁺]: 364.2302, found 364.2298 (-1.3 ppm). **28b**: R_f = 0.40 (20:80 EtOAc:Hex); IR (neat) ν_{max} 3433, 2245 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.42 – 7.28 (m, 5H), 4.55 (d, *J* 5.6 Hz, 1H), 4.53 (d, *J* 12.2 Hz, 1H), 4.50 (d, *J* 11.9 Hz, 1H), 4.35 (d, *J* 5.6 Hz, 1H), 3.85 (appt, *J* 4.2 Hz, 1H), 3.61 (dd, *J* 10.3, 3.9 Hz, 1H), 3.50 (dd, *J* 10.3, 4.6 Hz, 1H), 1.17 (s, 3H), 1.03 (s, 3H), 0.90 (s, 9H), 0.13 (s, 3H), 0.08 (s, 3H) ppm; ¹³C NMR (100.6 MHz, CDCl₃) δ 137.4, 128.6, 128.1, 127.9, 119.0,

78.4, 73.6, 71.6, 69.8, 41.1, 26.0, 21.4, 21.1, 18.3, -4.1, -5.0 ppm; HRMS calcd for C₂₀H₃₄O₃NSi [M+H⁺]: 364.23025, found 364.23016 (-0.2 ppm).

Compounds 4, 29, 30, 31, 32 and 33 from Scheme 7:

(+)-(5S,6S,7R)-5-[(Benzyloxy)methyl]-7-[bis(ethylthio)methyl]-2,2,3,3,6,9,9,10,10-nonamethyl-6-vinyl-4,8-dioxo-3,9-disilaundecane (4): A solution of cyanohydrin **16** (2.2 g, 4.5 mmol, 1.0 equiv.) in toluene (9.0 mL, 0.50 M) was cooled to 0 °C followed by dropwise addition of DIBAL-H (1.0 M in hexanes, 6.7 mL, 6.7 mmol, 1.4 equiv.). After stirring 1 hour at 0 °C, saturated aqueous Rochelle salt (15 mL) was added slowly and the biphasic mixture was warmed to room temperature, diluted with Et₂O (10 mL) and stirred vigorously for 2 hours. The aqueous layer was extracted with Et₂O (1 × 15 mL) and the combined organic layers dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was dissolved in EtOAc and 1N HCl (2:1, 30 mL) was added. The biphasic mixture was stirred vigorously for 1 hour at which point, Et₂O was added (15 mL), the layers separated, and the organic layer extracted with Et₂O (1 × 15 mL). The combined organic fractions were washed with water followed by brine, dried over MgSO₄ and concentrated *in vacuo* to afford the crude aldehyde (2.2 g, quantitative yield) which was used immediately for the next step. The aldehyde (2.2 g, 4.5 mmol, 1.0 equiv.) was dissolved in CH₂Cl₂ (22 mL, 0.20 M) and the resulting solution was cooled to -78 °C followed by addition of ethanethiol (1.0 mL, 14 mmol, 3.2 equiv.) and BF₃·OEt₂ (0.72 mL, 5.8 mmol, 1.3 equiv.). The resulting reaction mixture was stirred 4 hours at -78 °C before Et₃N (3.1 mL, 23 mL, 5.0 equiv.) was added dropwise with stirring for an additional 20 minutes. Saturated aqueous NaHCO₃ (25 mL) was added slowly and the biphasic mixture warmed to room temperature. After stirring vigorously for 30 minutes, the layers were separated, and the aqueous layer extracted with hexanes (2 × 20 mL). The combined organic fractions were washed with 1N NaOH (2 × 15 mL, to remove excess EtSH), water and brine, dried over MgSO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography (Hexanes/DCM) provided the pure dithioacetal **4** as a slightly yellow oil (1.9 g, 70% yield): R_f = 0.45 (Hexanes/ DCM 70:30); [α]_D²⁵ +3.6 (c=1.6, CH₂Cl₂); Molecular formula: C₃₁H₅₈O₃S₂Si₂; MW: 599.09; IR (neat) ν_{max} 2954, 2927, 2854, 1089 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.35 – 7.26 (m, 5H), 6.04 (dd, *J* 17.6, 10.9 Hz, 1H), 5.10 (dd, *J* 10.9, 0.9 Hz, 1H), 4.99 (dd, *J* 17.6, 1.0 Hz, 1H), 4.49 (d, *J* 11.9 Hz, 1H), 4.45 (d, *J* 11.9 Hz, 1H), 4.12 (dd, *J* 7.4, 1.0 Hz, 1H), 3.99 – 3.88 (m, 3H), 3.31 (dd, *J* 9.5, 7.6 Hz, 1H), 2.73 – 2.55 (m, 2H), 2.49 (q, *J* 7.4 Hz, 2H), 1.23 (td, *J* 7.4, 3.5 Hz, 6H), 1.05 (s, 3H), 0.92 (s, 9H), 0.84 (s, 9H), 0.24 (s, 3H), 0.10 (s, 3H), 0.02 (s, 3H), 0.02 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 143.9, 138.7, 128.3, 127.9, 127.4, 114.3, 82.6, 75.3, 73.6, 73.4, 54.7, 50.6, 27.0, 26.61, 26.58, 26.3, 19.0, 18.6, 15.9, 14.6, 14.4, -2.3, -3.5, -4.4, -4.7 ppm; HRMS calcd for C₃₁H₅₈O₃S₂Si₂Na [M+Na⁺]: 621.3258; found 621.3240 (-3.0 ppm).

(-)-1-((2R,3R,4S)-4-((S)-2-(Benzyloxy)-1-[(*tert*-butyldimethylsilyl)oxy]ethyl)-3-[(*tert*-butyldimethylsilyl)oxy]-2-(ethylthio)-4-methylhex-5-en-1-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (29): To a solution of dithioacetal **4** (60 mg, 0.10 mmol, 1.0 equiv.) in THF (0.50 mL, 0.20 M) at 0 °C, silylated thymine (0.50 M in DCE, 0.40 mL, 0.20 mmol, 2.0 equiv.) and iodine (51 mg, 0.20 mmol, 2.0 equiv.) were added. The resulting dark purple reaction mixture was stirred 16 hours at 0 °C before addition of saturated aqueous Na₂S₂O₃ (2 mL) followed by addition of a few drops of 2N NaOH. The biphasic mixture was warmed to room temperature and stirred vigorously until a clear homogeneous biphasic mixture was obtained. The aqueous layer was extracted with Et₂O (2 × 2 mL) and the combined organic fractions were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. ¹H NMR spectroscopic analysis of the unpurified product indicated the formation of only one diastereomer. Purification by flash chromatography provided thioaminal **29** as a white foam (44 mg, 66% yield): R_f = 0.54 (Hexanes/EtOAc, 70:30); [α]_D²⁵ -11 (c= 1.9, CH₂Cl₂); Molecular formula: C₃₄H₅₈N₂O₅SSi₂; MW: 663.08; IR (neat) ν_{max} 2927, 2855, 1676, 1089 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.02 (s, 1H), 7.63 (d, *J* 1.2 Hz, 1H), 7.35 – 7.28 (m, 5H), 6.01 – 5.94 (m, 2H), 5.17 (dd, *J* 10.9, 1.3 Hz, 1H), 5.06 (dd, *J* 17.7, 1.3 Hz, 1H), 4.45 (d, *J* 11.7 Hz, 1H), 4.41 (d, *J* 11.6 Hz, 1H), 4.23 (d, *J* 2.1 Hz, 1H), 4.13 (dd, *J* 7.0, 3.7 Hz, 1H), 3.55 (dd, *J* 10.0, 3.7

Hz, 1H), 3.31 (dd, *J* 10.0, 7.0 Hz, 1H), 2.41 – 2.24 (m, 2H), 1.93 (d, *J* 1.2 Hz, 3H), 1.21 (t, *J* 7.4 Hz, 3H), 1.11 (s, 3H), 0.97 (s, 9H), 0.79 (s, 9H), 0.12 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H), -0.01 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 163.6, 150.5, 141.0, 138.3, 138.1, 128.4, 128.0, 127.7, 116.1, 111.2, 79.5, 73.5, 73.4, 73.0, 64.9, 50.5, 26.6, 26.1, 24.3, 19.3, 18.5, 14.3, 13.9, 12.5, -1.8, -3.53, -3.57, -4.5 ppm; HRMS calcd for C₃₄H₅₈N₂O₅SSi₂Na [M+Na⁺]: 685.3497; found 685.3487 (-1.4 ppm).

(-)-1-((1S,2R,3S)-3-((S)-2-(Benzyloxy)-1-hydroxyethyl)-2-(tert-butyldimethylsilyloxy)-1-(ethylthio)-3-methylpent-4-en-1-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (30): To a solution of thioaminal **29** (66 mg, 0.10 mmol, 1.0 equiv.) in DCM/MeOH (1:1, 5 mL, 0.02M), TsOH·H₂O (95 mg, 0.50 mmol, 5.0 equiv.) was added. The resulting mixture was warmed to 50 °C and stirring was continued for 16 hours. The reaction mixture was cooled to room temperature and Et₃N (84 μL, 0.60 mmol, 6.0 equiv.) was added. After evaporation of the volatiles, the residue was purified by flash chromatography to afford **30** as a white foam (40 mg, 73% yield): *R*_f = 0.47 (Hexanes/EtOAc, 60:40); [α]_D²⁵ -51 (*c* = 2.0, CH₂Cl₂); Molecular formula: C₂₈H₄₄N₂O₅SSi; MW: 548.81; IR (neat) *v*_{max} 3427, 1678 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.87 (s, 1H), 7.77 (d, *J* 1.2 Hz, 1H), 7.35 – 7.31 (m, 5H), 6.14 (d, *J* 2.0 Hz, 1H), 5.92 (dd, *J* 17.6, 10.8 Hz, 1H), 5.18 (dd, *J* 10.8, 1.2 Hz, 1H), 5.04 (dd, *J* 17.7, 1.2 Hz, 1H), 4.56 (d, *J* 12.0 Hz, 1H), 4.51 (d, *J* 12.0 Hz, 1H), 4.21 (d, *J* 1.9 Hz, 1H), 4.13 (dd, *J* 8.4, 2.7 Hz, 1H), 3.49 (dd, *J* 10.0, 2.6 Hz, 1H), 3.33 (dd, *J* 10.0, 8.4 Hz, 1H), 2.48 – 2.23 (m, 2H), 1.96 (d, *J* 1.2 Hz, 3H), 1.25 (t, *J* 7.4 Hz, 3H), 1.12 (s, 3H), 0.94 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H) ppm, OH signal missing possibly due to exchange in CDCl₃; ¹³C NMR (126 MHz, CDCl₃) δ 163.6, 151.5, 140.5, 138.3, 138.1, 128.5, 127.9, 127.7, 117.0, 111.4, 79.3, 73.8, 73.4, 72.5, 64.4, 49.1, 26.5, 24.3, 19.1, 14.5, 14.4, 12.6, -1.4, -3.1 ppm; HRMS calcd for C₂₈H₄₄N₂O₅SSiNa [M+Na⁺]: 571.2632; found 571.2669 (+6.5 ppm).

(-)-1-((1S,2R,3S)-3-((S)-2-(Benzyloxy)-1-hydroxyethyl)-2-((tert-butyldimethylsilyloxy)-1-(ethylthio)-3-methylpent-4-en-1-yl)pyrimidine-2,4(1H,3H)-dione (31): To a 0 °C solution of dithioacetal **4** (72 mg, 0.12 mmol, 1.0 equiv.) in THF (0.50 mL, 0.24 M), silylated uracil (0.90 M in DCE, 0.25 mL, 0.24 mmol, 2.0 equiv.) and iodine (61 mg, 0.24 mmol, 2.0 equiv.) were added. The resulting dark purple reaction mixture was stirred 16 hours at 0 °C before addition of saturated aqueous Na₂S₂O₃ (2 mL) followed by addition of a few drops of 2N NaOH. The biphasic mixture was warmed to room temperature and stirred vigorously until a clear homogeneous biphasic mixture was obtained. The aqueous layer was extracted with Et₂O (2 × 2 mL) and the combined organic fractions were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to afford the crude thioaminal which was used directly in the next step. ¹H NMR spectroscopic analysis of the unpurified product indicated the formation of only one diastereomer. To a solution of the crude thioaminal in CH₂Cl₂/MeOH (1:1, 6.0 mL, 0.020 M), TsOH·H₂O (114 mg, 0.60 mmol, 5.0 equiv.) was added. The resulting mixture was warmed to 50 °C and stirred for 16 hours. The reaction mixture was cooled to room temperature and Et₃N (0.10 mL, 0.72 mmol, 6.0 equiv.) was added. After evaporation of the volatiles, the residue was purified by flash chromatography to afford **31** as a white foam (51 mg, 79% yield over two steps): *R*_f = 0.24 (Hexanes/EtOAc, 60:40); [α]_D²⁵ -48 (*c* = 1.1, CH₂Cl₂); Molecular formula: C₂₇H₄₂N₂O₅SSi; MW: 534.79; IR (neat) *v*_{max} 3427, 1684 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.87 (s, 1H), 7.97 (d, *J* 8.2 Hz, 1H), 7.35 – 7.27 (m, 5H), 6.13 (d, *J* 1.6 Hz, 1H), 5.93 (dd, *J* 17.6, 10.9 Hz, 1H), 5.79 (appdd, *J* 8.1, 2.2 Hz, 1H), 5.19 (d, *J* 10.9 Hz, 1H), 5.05 (d, *J* 17.7 Hz, 1H), 4.56 (d, *J* 11.9 Hz, 1H), 4.50 (d, *J* 11.9 Hz, 1H), 4.21 (d, *J* 1.9 Hz, 1H), 4.13 – 4.09 (m, 1H), 3.50 (dd, *J* 9.9, 2.5 Hz, 1H), 3.38 (s, 1H), 3.33 (dd, *J* 9.8, 8.6 Hz, 1H), 2.44 – 2.29 (m, 2H), 1.24 (t, *J* 7.4 Hz, 3H), 1.12 (s, 3H), 0.92 (s, 9H), 0.04 (s, 3H), 0.02 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 162.9, 151.4, 142.5, 140.4, 138.2, 128.5, 127.9, 127.8, 117.0, 102.8, 79.1, 73.6, 73.4, 72.3, 65.0, 49.1, 26.5, 24.4, 19.1, 14.42, 14.39, -1.5, -3.0 ppm; HRMS calcd for: C₂₇H₄₂N₂O₅SSiNa [M+Na⁺]: 557.2476; found 557.2470 (-1.1 ppm).

(-)-1-((2R,3R,4S,5S)-5-((Benzyloxy)methyl)-3-((tert-butyldimethylsilyloxy))-methyl-4-vinyltetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (32): To a stirred solution of **30** (0.21 g, 0.38 mmol, 1.0 equiv.) in

THF (3.8 mL, 0.10 M), $\text{Me}_2\text{S}(\text{SMe})\text{BF}_4$ (90 mg, 0.46 mmol, 1.2 equiv.) was added and the resulting mixture was stirred 2 hours at room temperature. The reaction mixture was then diluted with Et_2O (15 mL) followed by addition of saturated aqueous NaHCO_3 . The aqueous phase was extracted with Et_2O (1×15 mL) and the combined organic fractions were washed with brine, dried over MgSO_4 , filtered and concentrated *in vacuo*. Purification by flash chromatography on silica gel provided **32** as a white foam (0.42 g, 71% yield): $R_f = 0.49$ (Hexanes/ EtOAc , 60:40); $[\alpha]_{\text{D}}^{25} -12$ ($c = 0.23$, CH_2Cl_2); Molecular formula: $\text{C}_{26}\text{H}_{38}\text{N}_2\text{O}_5\text{Si}$; MW: 486.68; IR (neat) ν_{max} 3182, 3062, 2928, 1691, 1264 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) 7.92 (s, 1H), 7.76 (d, J 1.1 Hz, 1H), 7.39 – 7.30 (m, 5H), 6.14 (dd, J 17.5, 10.9 Hz, 1H), 6.09 (d, J 7.4 Hz, 1H), 5.29 (d, J 10.9 Hz, 1H), 5.25 (d, J 17.5 Hz, 1H), 4.64 (d, J 11.3 Hz, 1H), 4.54 (d, J 11.3 Hz, 1H), 4.37 (d, J 7.4 Hz, 1H), 3.89 (t, J 2.0 Hz, 1H), 3.77 (dd, J 10.7, 2.6 Hz, 1H), 3.55 (dd, J 10.7, 1.5 Hz, 1H), 1.38 (d, J 0.9 Hz, 3H), 1.33 (s, 3H), 0.81 (s, 9H), -0.04 (s, 3H), -0.16 (s, 3H) ppm; ^{13}C NMR (126 MHz, CDCl_3) δ 163.4, 150.8, 139.8, 137.4, 136.6, 128.9, 128.4, 127.6, 117.5, 111.4, 87.2, 86.7, 79.8, 73.6, 71.4, 49.6, 25.7, 18.0, 17.8, 11.7, -4.1, -4.8 ppm; HRMS calcd for: $\text{C}_{26}\text{H}_{38}\text{N}_2\text{O}_5\text{SiNa}$ $[\text{M}+\text{Na}^+]$: 509.2442; found 509.2447 (+0.9 ppm).

(-)-1-((2R,3R,4S,5S)-5-[(Benzyloxy)methyl]-3-[(tert-butyldimethylsilyloxy)-4-methyl-4-vinyltetrahydrofuran-2-yl]pyrimidine-2,4(1H,3H)-dione (33): To a stirred solution of **31** (0.12 g, 0.22 mmol, 1.0 equiv.) in THF (2.2 mL, 0.10 M), $\text{Me}_2\text{S}(\text{SMe})\text{BF}_4$ (55 mg, 0.28 mmol, 1.3 equiv.) was added and the resulting mixture was stirred 2 hours at room temperature. The reaction mixture was diluted with Et_2O (5 mL) followed by addition of saturated aqueous NaHCO_3 . The aqueous phase was extracted with Et_2O (1×15 mL) and the combined organic fractions were washed with brine, dried over MgSO_4 , filtered and concentrated *in vacuo*. Purification by flash chromatography on silica gel provided **33** as a white foam (81 mg, 80% yield): $R_f = 0.49$ (Hexanes/ EtOAc , 60:40); $[\alpha]_{\text{D}}^{25} -1.6$ ($c = 0.19$, CH_2Cl_2); Molecular formula: $\text{C}_{25}\text{H}_{36}\text{N}_2\text{O}_5\text{Si}$; MW: 472.66; IR (neat) ν_{max} 3183, 3064, 2928, 1686, 1265, 1059, 837 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.93 (d, $J = 8.2$ Hz, 1H), 7.88 (s, 1H), 7.44 – 7.34 (m, 5H), 6.08 (dd, $J = 17.5$, 10.8 Hz, 1H), 6.06 (d, $J = 7.3$ Hz, 1H), 5.30 (dd, $J = 10.9$, 0.7 Hz, 1H), 5.24 (dd, $J = 17.7$, 0.8 Hz, 1H), 5.21 (dd, $J = 8.2$, 2.5 Hz, 1H), 4.61 (d, $J = 10.4$ Hz, 1H), 4.43 (d, $J = 10.5$ Hz, 1H), 4.26 (d, $J = 7.3$ Hz, 1H), 3.88 (dd, $J = 2.2$, 1.7 Hz, 1H), 3.75 (dd, $J = 10.6$, 2.6 Hz, 1H), 3.57 (dd, $J = 10.6$, 1.4 Hz, 1H), 1.31 (s, 3H), 0.79 (s, 9H), -0.10 (s, 3H), -0.22 (s, 3H) ppm; ^{13}C NMR (126 MHz, CDCl_3) δ 162.7, 150.7, 141.2, 139.7, 137.2, 129.0, 128.7, 128.3, 117.6, 102.5, 87.4, 86.9, 79.9, 73.9, 71.3, 49.7, 25.7, 17.9, 17.7, -4.2, -4.9 ppm; HRMS calcd for: $\text{C}_{25}\text{H}_{36}\text{N}_2\text{O}_5\text{SiNa}$ $[\text{M}+\text{Na}^+]$: 495.2286; found 495.2291 (+1.0 ppm).

Compounds 34, 35, 36 and 37 from Scheme 8:

(+)-1-((2R,3R,4R,5S)-5-[(Benzyloxy)methyl]-3-hydroxy-4-(hydroxymethyl)-4-methyltetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (34): To a solution of alkene **32** (0.11 g, 0.22 mmol, 1.0 equiv.) in acetone/ H_2O (2:1, 2.2 mL, 0.10 M), NMO (0.10 g, 0.86 mmol, 4.0 equiv.) and OsO_4 (4% in H_2O , 70 μL , 0.050 equiv.) were added. The resulting mixture was warmed to 50 $^\circ\text{C}$ and stirring was continued for 16 hours. After cooling to room temperature, the reaction mixture was diluted with EtOAc (3 mL) and water (2 mL). The aqueous layer was extracted with EtOAc (2x3 mL) and the combined organic fractions were washed with brine, dried over MgSO_4 , filtered and concentrated *in vacuo* to provide the crude diol as a single diastereoisomer (unassigned stereochemistry) which was used directly in the next step. The crude diol (0.22 mmol, 1.0 equiv.) was dissolved in dioxane/ H_2O (9:1, 2.2 mL, 0.10 M) and the resulting solution was cooled to 0 $^\circ\text{C}$ followed by addition of NaIO_4 (94 mg, 0.44 mmol, 2.0 equiv.). The mixture was warmed to room temperature and stirring was continued for 3 hours. The reaction mixture was diluted with EtOAc (2 mL) and slowly poured into stirring cold saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$. After stirring 15 minutes, the aqueous phase was extracted with EtOAc (2x3 mL) and the combined organic fractions were washed with brine, dried over MgSO_4 , filtered and concentrated *in vacuo* to provide the crude aldehyde as a white solid. The crude aldehyde (0.22 mmol, 1.0 equiv.) was dissolved in THF (2.2 mL, 0.10 M) and the resulting solution cooled to -40 $^\circ\text{C}$. LiBH_4 (2.0 M in THF, 0.14 mL,

0.29 mmol, 1.3 equiv.) was added dropwise and stirring was continued for 2 hours. The reaction was quenched with slow addition of 0.05N HCl (2 mL) and warmed to room temperature. After stirring vigorously for 30 minutes, EtOAc (3 mL) was added and the aqueous phase extracted with EtOAc (2 × 3 mL). The combined organic fractions were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to provide the crude alcohol. The crude alcohol (0.22 mmol, 1.0 equiv.) was dissolved in THF (1.1 mL, 0.20 M) and the resulting solution was cooled to 0 °C. TBAF (1.0 M in THF, 0.33 mL, 0.33 mmol, 1.5 equiv.) was added and stirring at 0 °C was continued for 16 hours. The reaction mixture was diluted with EtOAc (3 mL) followed by addition of saturated aqueous NH₄Cl. The aqueous layer was extracted with EtOAc (2x3 mL) and the combined organic fractions were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to provide the crude diol. Purification by flash chromatography on silica gel provided the pure C5'-protected nucleoside **34** as a white foam (49 mg, 59% yield over 4 steps): R_f = 0.64 (CH₂Cl₂/MeOH, 90:10); [α]_D²⁵ +1.9 (c = 0.66, CH₂Cl₂/MeOH 10:1); Molecular formula: C₁₉H₂₄N₂O₆; MW: 376.41; IR (neat) ν_{max} 3412, 1685 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 10.97 (s, 1H), 7.60 (s, 1H), 7.38 – 7.28 (m, 5H), 5.76 (d, J 4.4 Hz, 1H), 5.01 (s, 1H), 4.62 (d, J 11.6 Hz, 1H), 4.58 (d, J 11.6 Hz, 1H), 4.42 (s, 1H), 4.10 (t, J 3.6 Hz, 1H), 3.82 (dd, J 10.9, 3.4 Hz, 1H), 3.77 (dd, J 10.9, 3.9 Hz, 1H), 3.63 (s, 2H), 3.57 (s, 1H), 1.52 (s, 3H), 1.19 (s, 3H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 164.5, 152.3, 137.4, 136.9, 128.8, 128.2, 127.9, 109.8, 91.8, 86.1, 78.4, 73.9, 69.2, 66.1, 48.0, 16.6, 12.3 ppm; HRMS calcd for C₁₉H₂₄N₂O₆Na [M+Na⁺]: 399.1527; found 399.1527 (0.0 ppm).

(+)-1-((2R,3R,4R,5S)-5-((Benzyloxy)methyl)-3-hydroxy-4-(hydroxymethyl)-4-methyltetrahydrofuran-2-yl)-pyrimidine-2,4(1H,3H)-dione (35): To a solution of alkene **33** (47 mg, 0.10 mmol, 1.0 equiv.) in acetone/H₂O (2:1, 1.0 mL, 0.10 M), NMO (47 mg, 0.40 mmol, 4.0 equiv.) and OsO₄ (4% in H₂O, 33 μL, 0.050 equiv.) were added. The resulting mixture was warmed to 50 °C and stirring was continued for 16 hours. After cooling to room temperature, the reaction mixture was diluted with EtOAc (2 mL) and water (1 mL). The aqueous layer was extracted with EtOAc (2 × 2 mL) and the combined organic fractions were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to provide the crude diol as a single diastereoisomer (unassigned stereochemistry) which was used directly in the next step. The crude diol was dissolved in dioxane/H₂O (9:1, 1.0 mL, 0.10 M) and the resulting solution cooled to 0 °C followed by addition of NaIO₄ (43 mg, 0.20 mmol, 2.0 equiv.). The mixture was warmed to room temperature and stirring was continued for 3 hours. The reaction mixture was diluted with EtOAc (2 mL) and slowly poured into stirring cold saturated aqueous Na₂S₂O₃. After stirring 15 minutes, the aqueous phase was extracted with EtOAc (2 × 3 mL). The combined organic fractions were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to provide the crude aldehyde as a white solid. The crude aldehyde was dissolved in THF (1.0 mL, 0.10 M) and the resulting solution cooled to -40 °C. LiBH₄ (2.0 M in THF, 50 μL, 0.10 mmol, 1.0 equiv.) was added dropwise and stirring was continued for 2 hours. The reaction was quenched with slow addition of 0.05N HCl (2.5 mL) and warmed to room temperature. After stirring vigorously for 30 minutes, EtOAc (3 mL) was added, and the aqueous phase was extracted with EtOAc (2 × 3 mL). The combined organic fractions were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to provide the crude alcohol. The crude alcohol was dissolved in THF (0.50 mL, 0.20 M) and the resulting solution cooled to 0 °C. TBAF (1.0 M in THF, 0.15 mL, 0.15 mmol, 1.5 equiv.) was added and stirring at 0 °C continued for 16 hours. The reaction mixture was diluted with EtOAc (3 mL) followed by addition of saturated aqueous NH₄Cl. The aqueous layer was extracted with EtOAc (2 × 3 mL) and the combined organic fractions were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to provide the crude diol. Purification by flash chromatography on silica gel provided the pure C5' protected nucleoside **35** as a white foam (21.7 mg, 59% yield over 4 steps): R_f = 0.61 (CH₂Cl₂/MeOH, 90:10); [α]_D²⁵ +5.0 (c = 0.64, CH₂Cl₂/MeOH 10:1); Molecular formula: C₁₈H₂₂N₂O₆; MW: 362.38; IR (neat) ν_{max} 3392, 1680 cm⁻¹; ¹H NMR (500 MHz, CD₃OD) δ 7.99 (d, J 8.1 Hz, 1H), 7.42 – 7.30 (m, 5H), 5.93 (d, J 6.9 Hz, 1H), 5.31 (d, J 8.1 Hz, 1H), 4.62

(d, *J* 10.8 Hz, 1H), 4.49 (d, *J* 10.8 Hz, 1H), 4.08 (d, *J* 6.9 Hz, 1H), 3.99 (t, *J* 2.9 Hz, 1H), 3.89 – 3.79 (m, 3H), 3.59 (d, *J* 10.9 Hz, 1H), 1.24 (s, 3H) ppm, OH and NH signals missing possibly due to exchange in CD₃OD; ¹³C NMR (126 MHz, CD₃OD) δ 166.1, 152.9, 142.9, 139.1, 129.7, 129.4, 129.2, 102.6, 89.6, 87.4, 77.8, 74.7, 71.5, 66.1, 49.0, 17.5 ppm; HRMS calcd for C₁₈H₂₂N₂O₆Na [M+Na⁺]: 385.1370; found 385.1369 (-0.3 ppm).

(+)-1-[(2R,3R,4R,5S)-3-Hydroxy-4,5-bis(hydroxymethyl)-4-(methyltetrahydrofuran-2-yl)]-5-methylpyrimidine-2,4(1H,3H)-dione (36): To a -40 °C solution of benzyl ether **34** (47 mg, 0.13 mmol, 1.0 equiv.) in CH₂Cl₂ (3.1 mL, 0.025 M), BCl₃ (1.0 M in CH₂Cl₂, 0.63 mL, 0.63 mmol, 5.0 equiv.) was added dropwise. The reaction mixture was stirred for 3 hours, at which point, methanol (0.10 mL) was added. With warming to room temperature, stirring was continued for 30 minutes and the volatiles removed under reduced pressure. ¹H NMR analysis of the crude reaction mixture showed an 8:1 mixture of the product and starting material. Purification by flash chromatography (Biotage, C18 reverse phase, Water/MeOH) provided nucleoside **36** as a white foam (16.4 mg, 46% yield): [α]_D²⁵ +3.2 (*c* = 1.3, MeOH); Molecular formula: C₁₂H₁₈N₂O₆; MW: 286.28; IR (neat) ν_{max} 2322, 1667 cm⁻¹; ¹H NMR (500 MHz, CD₃OD) δ 7.99 (d, *J* 1.1 Hz, 1H), 5.90 (d, *J* 6.9 Hz, 1H), 4.23 (d, *J* 6.8 Hz, 1H), 3.88 – 3.78 (m, 3H), 3.71 (d, *J* 11.2 Hz, 1H), 3.57 (d, *J* 11.2 Hz, 1H), 1.89 (d, *J* 0.9 Hz, 3H), 1.15 (s, 3H) ppm, OH and NH signals missing possibly due to exchange in CD₃OD; ¹³C NMR (126 MHz, CD₃OD) δ 166.4, 153.1, 138.7, 111.6, 89.6, 88.5, 77.0, 65.5, 62.7, 48.6, 17.8, 12.5 ppm; HRMS calcd for C₁₂H₁₈N₂O₆Na [M+Na⁺]: 309.1057; found 309.1065 (+2.6 ppm). See supporting information for proof of structure.

(+)-1-[(2R,3R,4R,5S)-3-Hydroxy-4,5-bis(hydroxymethyl)-4-methyltetrahydrofuran-2-yl]pyrimidine-2,4(1H,3H)-dione (37): To a -40 °C solution of benzyl ether **35** (27 mg, 75 μmol, 1.0 equiv.) in CH₂Cl₂ (32 mL, 0.025 M), BCl₃ (1.0 M in CH₂Cl₂, 0.37 mL, 0.37 mmol, 5.0 equiv.) was added dropwise. The stirred reaction mixture was slowly warmed to -20 °C over 2 hours and stirred for 1 more hour at -20 °C, at which point methanol (0.10 mL) was added. The cooling bath was removed and stirring continued for 30 minutes. The volatiles were removed under reduced pressure. Purification by flash chromatography (Biotage, C18 reverse phase, Water/MeOH) provided the nucleoside **37** as a white foam (16 mg, 79% yield): [α]_D²⁵ +20 (*c* = 0.4, MeOH); Molecular formula: C₁₁H₁₆N₂O₆; MW: 272.26; IR (neat) ν_{max} 3369, 1681 cm⁻¹; ¹H NMR (500 MHz, CD₃OD) δ 8.12 (d, *J* 8.1 Hz, 1H), 5.90 (d, *J* 6.6 Hz, 1H), 5.71 (d, *J* 8.0 Hz, 1H), 4.21 (d, *J* 6.6 Hz, 1H), 3.88 – 3.85 (m, 1H), 3.85 – 3.76 (m, 2H), 3.68 (d, *J* 11.1 Hz, 1H), 3.55 (d, *J* 11.1 Hz, 1H), 1.16 (s, 3H) ppm, OH and NH signals missing possibly due to exchange in CD₃OD; ¹³C NMR (126 MHz, CD₃OD) δ 166.7, 153.3, 142.9, 102.9, 90.1, 88.7, 77.4, 65.4, 62.7, 48.7, 17.7 ppm; HRMS calcd for C₁₁H₁₆N₂O₆Na [M+Na⁺]: 295.0901; found 295.0902 (+0.3 ppm).

Acknowledgements

Funding for this research has been granted from Natural Sciences and Engineering Research Council (NSERC) and Canadian Glycomics Network (Glyconet <http://10.13039/501100009056>). This research was enabled in part by WestGrid (www.westgrid.ca) and Compute Canada–Calcul Canada (www.computecanada.ca).

Supplementary Material

The supporting information is available free of charge on the website and contains proof of structures, X-ray crystallographic data for compound **S20a**, ¹H NMR and ¹³C NMR spectra for all new compounds along with details concerning the computational method, energies, and Cartesian coordinates for intermediate **E**.

References

1. Jordheim, L. P.; Durantel, D.; Zoulim, F.; Dumontet, C. *Nat. Rev. Drug Discovery* **2013**, *12*, 447-464.
<http://dx.doi.org/10.1038/nrd4010>.
2. Seley-Radtke, K. L.; Yates, M. K. *Antiviral Res.* **2018**, *154*, 66-86.
<http://dx.doi.org/10.1016/j.antiviral.2018.04.004>.
3. Tsesmetzis, N.; Paulin, C. B. J.; Rudd, S. G.; Herold, N. *Cancers* **2018**, *10*, 240.
<http://dx.doi.org/10.3390/cancers10070240>.
4. Asselah, T. *Expert Opin. Pharmacother.* **2014**, *15*, 121-130.
<http://dx.doi.org/10.1517/14656566.2014.857656>.
5. Guindon, Y.; Mochirian, P.; Nemer, M.; Prévost, M. Nucleoside Analogues and Methods of use thereof, 2017, PCT/CA2017/051096.
6. Guindon, IRCM, Patent US8361988B2 (2013) and US8846636B2 (2014) US 62/218,220 (Sept 2015)
7. Tambutet, G.; Becerril-Jimenez, F.; Dostie, S.; Simard, R.; Prevost, M.; Mochirian, P.; Guindon, Y. *Org. Lett.* **2014**, *16*, 5698-5701.
<http://dx.doi.org/10.1021/ol502777r>.
8. Dostie, S.; Prevost, M.; Mochirian, P.; Tanveer, K.; Andrella, N.; Rostami, A.; Tambutet, G.; Guindon, Y. *J. Org. Chem.* **2016**, *81*, 10769-10790.
<http://dx.doi.org/10.1021/acs.joc.6b01845>.
9. Panda, A.; Satpati, S.; Dixit, A.; Pal, S. *RSC Adv.*, **2016**, *6*, 11233-11239.
<http://dx.doi.org/10.1039/c5ra26416b>.
10. Panda, A.; Islam, S.; Santra, M.; Pal, S. *RSC Adv.*, **2015**, *5*, 82450-82459.
<http://dx.doi.org/10.1039/c5ra19080k>.
11. Sells, T.; Nair, V. *Tet. Lett.*, **1993**, *34*, 3527-3530.
[https://dx.doi.org/10.1016/S0040-4039\(00\)73627-6](https://dx.doi.org/10.1016/S0040-4039(00)73627-6).
12. Zong, G.; Yan, X.; Bi, J.; Jiang, R.; Qin, Y.; Yuan, H.; Lu, H.; Dong, Y.; Jin, S.; Zhang, J. *PLoS One* **2017**, *12*, e0181646.
<http://dx.doi.org/10.1371/journal.pone.0181646>.
13. Sun, J.; Dou, Y.; Ding, H.; Yang, R.; Sun, Q.; Xiao, Q. *Mar Drugs* **2012**, *10*, 881-889.
<http://dx.doi.org/10.3390/md10040881>.
14. Reddy, E. R.; Trivedi, R.; Sudheer Kumar, B.; Sirisha, K.; Sarma, A. V.; Sridhar, B.; Prakasham, R. S. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 3447-3452.
<http://dx.doi.org/10.1016/j.bmcl.2016.06.049>.
15. Gonçalves-Pereira, R.; Pereira, M.; Serra, S.; Loesche, A.; Csuk, R.; Silvestre, S.; Costa, P.; Conceição Oliveira, M.; Xavier, N. *Eur. J. Org. Chem.* **2018**, 2667-2681.
<http://dx.doi.org/10.1002/ejoc.201800245>.
16. Guindon, Y.; Houde, K.; Prevost, M.; Cardinal-David, B.; Landry, S. R.; Daoust, B.; Bencheqroun, M.; Guerin, B. *J. Am. Chem. Soc.* **2001**, *123*, 8496-8501.
<https://dx.doi.org/10.1021/ja010805m>.
17. Brazeau, J. F.; Mochirian, P.; Prevost, M.; Guindon, Y. *J. Org. Chem.* **2009**, *74*, 64-74.
<http://dx.doi.org/10.1021/jo8021583>.
18. Kita, Y.; Yasuda, H.; Tamura, O.; Itoh, F.; Ya, Y. K.; Tamura, Y. *Tetrahedron Lett.* **1985**, *26*, 5777-5780.
[https://dx.doi.org/10.1016/S0040-4039\(00\)98924-X](https://dx.doi.org/10.1016/S0040-4039(00)98924-X).
19. Dong, S.; Parker, G. D.; Tei, T.; Paquette, L. A. *Org. Lett.* **2006**, *8*, 2429-2431.

- <http://dx.doi.org/10.1021/ol060827j>.
20. Paquette, L. A.; Parker, G. D.; Tei, T.; Dong, S. *J. Org. Chem.* **2007**, *72*, 7125-7134.
<http://dx.doi.org/10.1021/jo070861r>.
21. Paquette, L. A.; Parker, G. D.; Tei, T.; Dong, S. *J. Org. Chem.* **2009**, *74*, 1812.
<http://dx.doi.org/10.1021/jo9001382>.
22. Duplessis, M.; Waltz, M. E.; Bencheqroun, M.; Cardinal-David, B.; Guindon, Y. *Org. Lett.* **2009**, *11*, 3148-3151.
<http://dx.doi.org/10.1021/Ol901126y>.
23. Giese, B.; Damm, W.; Wetterich, F.; Zeltz, H.G.; Rancourt, J.; Guindon, Y. *Tetrahedron Lett.* **1993**, *34*, 5885-5888.
[https://dx.doi.org/10.1016/S0040-4039\(00\)73805-6](https://dx.doi.org/10.1016/S0040-4039(00)73805-6).
24. Ward, D. E.; Hrapchak, M. J.; Sales, M. *Org. Lett.* **2000**, *2*, 57-60.
<http://dx.doi.org/10.1021/ol991198z>.
25. North, M.; Usanov, D. L.; Young, C. *Chem. Rev.* **2008**, *108*, 5146-5226.
<http://dx.doi.org/10.1021/cr800255k>.
26. Denmark, S. E.; Chung, W. J. *J. Org. Chem.* **2006**, *71*, 4002-4005.
<http://dx.doi.org/10.1021/jo060153q>.
27. Shenoy, S. R.; Smith, D. M.; Woerpel, K. A. *J. Am. Chem. Soc.* **2006**, *128*, 8671-8677.
<http://dx.doi.org/10.1021/ja061110u>.
28. Kurono, N.; Yamaguchi, M.; Suzuki, K.; Ohkuma, T. *J. Org. Chem.* **2005**, *70*, 6530-6532.
<http://dx.doi.org/10.1021/jo050791t>.
29. Yajima, T.; Okada, K.; Nagano, H. *Tetrahedron* **2004**, *60*, 5683-5693.
<http://dx.doi.org/10.1016/j.tet.2004.05.020>.
30. Nagano, H.; Ohkouchi, H.; Yajima, T. *Tetrahedron* **2003**, *59*, 3649-3663.
[http://dx.doi.org/10.1016/S0040-4020\(03\)00421-6](http://dx.doi.org/10.1016/S0040-4020(03)00421-6).
31. Nagano, H.; Toi, S.; Matsuda, M.; Hirasawa, T.; Hirasawa, S.; Yajima, T. *J. Chem. Soc. Perkin Trans. I* **2002**, 2525-2538.
<http://dx.doi.org/10.1039/b205613p>.
32. However, PMBCl or PMBOH could not be observed in the NMR spectra.
33. Gau, H.-M.; Lee, C.-S.; Lin, C.-C.; Jiang, M.-K.; Ho, Y.-C.; Kuo, C.N. *J. Am. Chem. Soc.* **1996**, *118*, 2936-2941.
<http://dx.doi.org/10.1021/ja952730q>.
34. Gaussian 09, Revision D.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, **2013**.
35. Zhao, Y.; Truhlar, D. G. *Acc. Chem. Res.* **2008**, *41*, 157-167.
<http://dx.doi.org/10.1021/ar700111a>.
36. Cossi, M.; Scalmani, G.; Rega, N.; Barone, V. *J. Chem. Phys.* **2002**, *117*, 43-54.

- <http://dx.doi.org/10.1063/1.1480445>.
37. Godin, F.; Duplessis, M.; Buonomano, C.; Trinh, T.; Houde, K.; Chapdelaine, D.; Rodrigue, J.; Boutrosa, A.; Guindon, Y. *Org. Chem. Front.*, **2014**, *1*, 974-982.
<http://dx.doi.org/10.1039/c4qo00142g>.
38. Kang, M.; Park, J.; Pedersen, S. F. *Synlett* **1997**, 41-43.
<http://dx.doi.org/10.1055/s-1997-709>.
39. Park, J.; Pedersen, S. F. *J. Org. Chem.* **1990**, *55*, 5924-5926.
<http://dx.doi.org/10.1021/jo00311a002>.
40. Chapdelaine, D.; Cardinal-David, B.; Prevost, M.; Gagnon, M.; Thumin, I.; Guindon, Y. *J. Am. Chem. Soc.* **2009**, *131*, 17242-17245.
<http://dx.doi.org/10.1021/ja905452f>.
41. Prevost, M.; Dostie, S.; Waltz, M. E.; Guindon, Y. *J. Org. Chem.* **2014**, *79*, 10504-10525.
<http://dx.doi.org/10.1021/jo502181a>.
42. Solsona, J.; Romea, P.; Urpi, F.; Vilarrasa, J. *Org. Lett.* **2002**, *4*, 519-522.
<http://dx.doi.org/10.1021/ol0274054>.
43. De Esch, I. J.; Gaffar, A.; Menge, W. M.; Timmerman, H. *Bioorg. Med. Chem.* **1999**, *7*, 3003-3009.
[https://dx.doi.org/10.1016/S0968-0896\(99\)00253-9](https://dx.doi.org/10.1016/S0968-0896(99)00253-9).
44. Maulucci, N.; Izzo, I.; Bifulco, G.; Aliberti, A.; De Cola, C.; Comegna, D.; Gaeta, C.; Napolitano, A.; Pizza, C.; Tedesco, C.; Flot, D.; De Riccardis, F. *Chem. Commun. (Camb)* **2008**, 3927-3929.
<http://dx.doi.org/10.1039/b806508j>.
45. Iseki, K.; Kuroki, Y.; Asada, D.; Takahashi, M.; Kishimoto, S.; Kobayashi, Y. *Tetrahedron* **1997**, *53*, 10271-10280.
[https://dx.doi.org/10.1016/S0040-4020\(97\)00683-2](https://dx.doi.org/10.1016/S0040-4020(97)00683-2).